US20220243194A1 - Targeted rna editing by leveraging endogenous adar using engineered rnas - Google Patents

Targeted rna editing by leveraging endogenous adar using engineered rnas Download PDF

Info

Publication number
US20220243194A1
US20220243194A1 US17/626,440 US202017626440A US2022243194A1 US 20220243194 A1 US20220243194 A1 US 20220243194A1 US 202017626440 A US202017626440 A US 202017626440A US 2022243194 A1 US2022243194 A1 US 2022243194A1
Authority
US
United States
Prior art keywords
rna
drna
sequence
target
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/626,440
Other languages
English (en)
Inventor
Wensheng Wei
Zongyi YI
Liang Qu
Feng Tian
Chunhui Wang
Shiyou Zhu
Zhuo ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Original Assignee
Peking University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University filed Critical Peking University
Assigned to PEKING UNIVERSITY reassignment PEKING UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QU, Liang, TIAN, FENG, WANG, Chunhui, WEI, WENSHENG, YI, Zongyi, ZHOU, Zhuo, ZHU, Shiyou
Assigned to PEKING UNIVERSITY reassignment PEKING UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: QU, Liang, TIAN, FENG, WANG, Chunhui, WEI, WENSHENG, YI, Zongyi, ZHOU, Zhuo, ZHU, Shiyou
Publication of US20220243194A1 publication Critical patent/US20220243194A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Definitions

  • the present disclosure relates generally to methods and compositions for editing RNAs using an engineered RNA capable of recruiting an adenosine deaminase to deaminate one or more adenosines in target RNAs.
  • Genome editing is a powerful tool for biomedical research and development of therapeutics for diseases. Editing technologies using engineered nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and Cas proteins of CRISPR system have been applied to manipulate the genome in a myriad of organisms. Recently, taking advantage of the deaminase proteins, such as Adenosine Deaminase Acting on RNA (ADAR), new tools were developed for RNA editing. In mammalian cells, there are three types of ADAR proteins, Adar1 (two isoforms, p110 and p150), Adar2 and Adar3 (catalytically inactive).
  • ADAR proteins Adar1 (two isoforms, p110 and p150), Adar2 and Adar3 (catalytically inactive).
  • the catalytic substrate of ADAR protein is double-stranded RNA, and ADAR can remove the —NH2 group from an adenosine (A) nucleobase, changing A to inosine (I).
  • A adenosine
  • I is recognized as guanosine (G) and paired with cytidine (C) during subsequent cellular transcription and translation processes.
  • the ADAR protein or its catalytic domain was fused with a ⁇ N peptide, a SNAP-tag or a Cas protein (dCas13b), and a guide RNA was designed to recruit the chimeric ADAR protein to the target site.
  • overexpressing ADAR1 or ADAR2 proteins together with an R/G motif-bearing guide RNA was also reported to enable targeted RNA editing.
  • ADAR-mediated RNA editing technologies have certain limitations.
  • the most effective in vivo delivery for gene therapy is through viral vectors, but the highly desirable adeno-associated virus (AAV) vectors are limited with the cargo size ( ⁇ 4.5 kb), making it challenging for accommodating both the protein and the guide RNA.
  • AAV adeno-associated virus
  • over-expression of ADAR1 has recently been reported to confer oncogenicity in multiple myelomas due to aberrant hyper-editing on RNAs, and to generate substantial global off-targeting edits.
  • ectopic expression of proteins or their domains of non-human origin has potential risk of eliciting immunogenicity.
  • pre-existing adaptive immunity and p53-mediated DNA damage response may compromise the efficacy of the therapeutic protein, such as Cas9.
  • the present application provides methods of RNA editing using ADAR-recruiting RNAs (“dRNA” or “arRNA”) which are capable of leveraging endogenous Adenosine Deaminase Acting on RNA (“ADAR”) proteins for the RNA editing.
  • dRNA ADAR-recruiting RNAs
  • ADAR Adenosine Deaminase Acting on RNA
  • engineered dRNAs or constructs comprising a nucleic acid encoding the engineered dRNAs used in these methods, and compositions and kits comprising the same.
  • methods for treating or preventing a disease or condition in an individual comprising editing a target RNA associated with the disease or condition in a cell of the individual.
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the dRNA is a circular RNA or capable of forming a circular RNA.
  • the dRNA is a linear RNA capable of forming a circular RNA.
  • the dRNA further comprises a 3′ ligation sequence and a 5′ ligation sequence.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least partially complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are about 20 to about 75 nucleotides in length.
  • the dRNA is circularized by an RNA ligase.
  • the RNA ligase is RNA ligase RtcB.
  • the RNA ligase RtcB is expressed endogenously in the host cell.
  • the dRNA is a circular RNA.
  • the method comprises introducing a construct comprising a nucleic acid encoding the dRNA into the host cell.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA and a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the 3′ twister sequence is twister P3 U2A and the 5′ twister sequence is twister P1.
  • the 5′ twister sequence is twister P3 U2A and the 3′ twister sequence is twister P1.
  • dRNA deaminase-recruiting RNA
  • RNA sequence that is at least partially complementary to the target RNA
  • small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence
  • dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • ADAR adenosine deaminase acting on RNA
  • the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”). In some embodiments, the dRNA comprises a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (3′ snoRNA sequence”). In some embodiments, the snoRNA sequence is at least about 70 nucleotides in length. In some embodiments, the 3′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 1. In some embodiments, the 5′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 2. In some embodiments, the snoRNA sequence is a C/D Box snoRNA sequence.
  • the snoRNA sequence is an H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is a composite C/D Box and H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is an orphan snoRNA sequence. In some embodiments, the method comprises introducing a construct comprising a nucleic acid encoding the dRNA into the host cell. In some embodiments, the construct further comprises a promoter operably linked to the nucleic acid encoding the dRNA. In some embodiments, the promoter is a polymerase II promoter (“Pol II promoter”). In some embodiments, the construct is a viral vector or a plasmid. In some embodiments, the construct is an AAV vector.
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked the nucleic acid encoding the dRNA.
  • Polymerase II promoter operably linked the nucleic acid encoding the dRNA.
  • the pol II promoter is a CMV promoter.
  • the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 3.
  • the construct is a viral vector or a plasmid.
  • the construct is an AAV vector.
  • the ADAR is endogenously expressed by the host cell.
  • the host cell is a T cell.
  • the targeting RNA sequence is more than 50 nucleotides in length. In some embodiments, the targeting RNA sequence is about 100 to about 180 nucleotides in length. In some embodiments, the targeting RNA sequence is about 100 to about 150 nucleotides in length.
  • the targeting RNA sequence comprises a cytidine, adenosine or uridine directly opposite the target adenosine in the target RNA. In some embodiments, the targeting RNA sequence comprises a cytidine mismatch directly opposite the target adenosine in the target RNA. In some embodiments, the cytidine mismatch is located at least 20 nucleotides away from the 3′ end of the targeting RNA sequence, and at least 5 nucleotides away from the 5′ end of the targeting RNA sequence. In some embodiments, the targeting RNA sequence further comprises one or more guanosines each opposite a non-target adenosine in the target RNA. In some embodiments, the targeting RNA sequence comprises two or more consecutive mismatch nucleotides opposite a non-target adenosine in the target RNA.
  • the 5′ nearest neighbor of the target adenosine in the target RNA is a nucleotide selected from U, C, A and G with the preference U>C ⁇ A>G and the 3′ nearest neighbor of the target adenosine in the target RNA is a nucleotide selected from G, C, A and U with the preference G>C>A ⁇ U.
  • the target adenosine is in a three-base motif selected from the group consisting of UAG, UAC, UAA, UAU, CAG, CAC, CAA, CAU, AAG, AAC, AAA, AAU, GAG, GAC, GAA and GAU in the target RNA.
  • the three-base motif is UAG
  • the targeting RNA comprises an A directly opposite the uridine in the three-base motif, a cytidine directly opposite the target adenosine, and a cytidine, guanosine or uridine directly opposite the guanosine in the three-base motif.
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA.
  • the target RNA is a pre-messenger RNA.
  • the method further comprises introducing an inhibitor of ADAR3 to the host cell. In some embodiments, the method further comprises introducing a stimulator of interferon to the host cell. In some embodiments, the method comprises introducing a plurality of dRNAs or constructs each targeting a different target RNA. In some embodiments, the method further comprises introducing an ADAR (e.g., exogenous ADAR) to the host cell. In some embodiments, the efficiency of editing the target RNA is at least 40%. In some embodiments, the construct or the dRNA does not induce immune response. In some embodiments, the ADAR is an ADAR1 comprising an E1008 mutation.
  • deamination of the target adenosine in the target RNA results in a missense mutation, an early stop codon, aberrant splicing, or alternative splicing in the target RNA, or reversal of a missense mutation, an early stop codon, aberrant splicing, or alternative splicing in the target RNA.
  • deamination of the target adenosine in the target RNA results in point mutation, truncation, elongation and/or misfolding of the protein encoded by the target RNA, or a functional, full-length, correctly-folded and/or wild-type protein by reversal of a missense mutation, an early stop codon, aberrant splicing, or alternative splicing in the target RNA.
  • the host cell is a eukaryotic cell.
  • the host cell is a mammalian cell.
  • the host cell is a human or mouse cell.
  • edited RNAs or host cells having the edited RNAs produced by any one of the methods provided in the above three aspects are also provided herein.
  • RNA associated with the disease or condition in a cell of the individual comprising editing a target RNA associated with the disease or condition in a cell of the individual according to any one of the methods provided above.
  • the disease or condition is a hereditary genetic disease or a disease or condition associated with one or more acquired genetic mutations.
  • the target RNA has a G to A mutation.
  • the disease or condition is a monogenetic disease or condition.
  • the disease or condition is a polygenetic disease or condition.
  • the target RNA is TP53, and the disease or condition is cancer.
  • the target RNA is IDUA, and the disease or condition is Mucopolysaccharidosis type I (MPS I).
  • the target RNA is COL3A1, and the disease or condition is Ehlers-Danlos syndrome.
  • the target RNA is BMPR2, and the disease or condition is Joubert syndrome.
  • the target RNA is FANCC, and the disease or condition is Fanconi anemia.
  • the target RNA is MYBPC3, and the disease or condition is primary familial hypertrophic cardiomyopathy.
  • the target RNA is IL2RG, and the disease or condition is X-linked severe combined immunodeficiency.
  • a deaminase-recruiting RNAs for editing a target RNA comprising a targeting RNA sequence that is at least partially complementary to the target RNA, wherein the dRNA is capable of recruiting an Adenosine Deaminase Acting on RNA (ADAR), and wherein the dRNA is circular or is capable of forming a circular RNA.
  • the dRNA is a linear RNA capable of forming a circular RNA.
  • the dRNA further comprises a 3′ ligation sequence and a 5′ ligation sequence. In some embodiments, the 3′ ligation sequence and the 5′ ligation sequence are at least partially complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are about 20 to about 75 nucleotides in length.
  • the dRNA is a circular RNA.
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA. Also provided herein are constructs comprising a nucleic acid encoding the dRNA as described in this aspect.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA and a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the 3′ twister sequence is twister P3 U2A and the 5′ twister sequence is twister P1.
  • the 5′ twister sequence is twister P3 U2A and the 3′ twister sequence is twister P1.
  • host cells comprising the construct or dRNA as described in this aspect.
  • kits for editing a target RNA in a host cell comprising the construct or dRNA as described in this aspect.
  • dRNA deaminase-recruiting RNA
  • RNA sequence that is at least partially complementary to the target RNA
  • small nucleolar RNA (snoRNA) sequence at the 3′ and/or 5′ ends of the targeting RNA sequence
  • dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • ADAR adenosine deaminase acting on RNA
  • the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”). In some embodiments, the dRNA comprises a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (3′ snoRNA sequence”). In some embodiments, the snoRNA sequence is at least about 70 nucleotides in length. In some embodiments, the 3′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 1. In some embodiments, the 5′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 2. In some embodiments, the snoRNA sequence is a C/D Box snoRNA sequence.
  • the snoRNA sequence is an H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is a composite C/D Box and H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is an orphan snoRNA sequence. Also provided herein are constructs comprising a nucleic acid encoding the dRNA as described in this aspect. In some embodiments, the construct further comprises a promoter operably linked to the nucleic acid encoding the dRNA. In some embodiments, the promoter is a polymerase II promoter (“Pol II promoter”).
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA.
  • host cells comprising the construct or dRNA as described in this aspect.
  • kits for editing a target RNA in a host cell comprising the construct or dRNA as described in this aspect.
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • Polymerase II promoter operably linked to the nucleic acid encoding the dRNA.
  • the pol II promoter is a CMV promoter.
  • the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 3.
  • the construct is a viral vector or a plasmid.
  • the construct is an AAV vector.
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA.
  • host cells comprising the construct as described in this aspect.
  • kits for editing a target RNA in a host cell comprising the construct as described in this aspect.
  • FIG. 1 depicts FACS analysis after transfection of a plasmid expressing arRNA driven by a pol II promoter (CMV) and a plasmid expressing arRNA driven by a Pol III promoter (U6) for 48 hours.
  • CMV pol II promoter
  • U6 plasmid expressing arRNA driven by a Pol III promoter
  • FIGS. 2A-2C depict Sno-arRNA 151 flanked by snoRNA ends mediated targeted RNA editing on Reporter mRNA.
  • FIG. 2A shows a schematic of arRNA-expressing plasmid. The 151-nt arRNA targeting fluorescence Reporter-1 was expressed under human U6 promoter.
  • FIG. 2B shows the FACS results of sno-arRNA or arRNA transfection results. The sno-arRNA 151 , arRNA 151 , sno-Ctrl RNA 151 or Ctrl RNA 151 was transfected into HEK293T cells along with Reporter-expressing plasmids.
  • FIG. 2C shows quantification of the FACS results in FIG. 2B .
  • FIGS. 3A-3C depict editing efficacy with CMV-promoter expressed sno-arRNA and hU6 promoter expressed sno-arRNA.
  • FIG. 3A shows the quantificational FACS results of hU6-derived sno-arRNA or arRNA at different time point.
  • FIG. 3B shows the quantificational FACS results of CMV or hU6 derived arRNA at different time point.
  • FIG. 3C shows the quantificational FACS results of CMV or hU6 derived sno-arRNA at different time point.
  • FIGS. 4A-4E depict editing efficacy using circular arRNA in the LEAPER system.
  • FIG. 4A shows a schematic of circular arRNA expression. Circular arRNA transcript was flanked by 5′ and 3′ ligation sequence, which were respectively flanked by 5′-Twister P3 U2A and 3′-Twister P1 ribozymes undergoing self-cleavage. The resulting RNA ends were recognized by RtcB for ligation.
  • FIG. 4B shows a schematic of the Reporter-1 and Reporter-3. mCherry and EGFP genes were linked by sequences containing 3 ⁇ (for Reporter-1) or 1 ⁇ (for Reporter-3) GGGGS-coding region and an in-frame UAG stop codon.
  • FIG. 4C shows results of an experiment, in which HEK293T cells stably expressing the Reporter-1 seeded in 12-well plates (3 ⁇ 10 5 cells/well) were transfected with the 1 ⁇ g of circular arRNA 71 , circular arRNA 25-71-25 , circular arRNA 50-71-50 , circular arRNA 111 , circular arRNA 25-111-25 , circular arRNA 50-111-50 , circular Ctrl RNA 123 (non-target sequence), arRNA 71 , Ctrl RNA 71 , arRNA 111 , Ctrl RNA 111 expressing plasmid respectively.
  • FIG. 4D shows results of an experiment, in which HEK293T cells stably expressing the Reporter-3 seeded in 12-well plates (3 ⁇ 10 5 cells/well) were transfected with the 1 ⁇ g of Ctrl RNA 151 (circular), 31-, 51-, 71-, 91-, 111-, 131-, 151-nt circular arRNA expressing plasmid respectively. FACS analyses were performed 2 days post transfection. The ratios of EGFP+ cells were normalized by transfection efficiency.
  • FIG. 4D shows results of an experiment, in which HEK293T cells stably expressing the Reporter-3 seeded in 12-well plates (3 ⁇ 10 5 cells/well) were transfected with the 1 ⁇ g of Ctrl RNA 151 (circular), 31-, 51-, 71-, 91-, 111-, 131-, 151-nt circular arRNA expressing plasmid respectively. FACS analyses were performed 2 days post transfection. The ratios of
  • 4E shows results of an experiment, in which HeLa and A549 cells seeded in 12-well plates (2 ⁇ 10 5 cells/well) were co-transfected with the 0.5 ⁇ g of reporter-1 expressing plasmid and the 0.5 ⁇ g of circular arRNA 111 expressing plasmid respectively. FACS analyses were performed 2 days post transfection. The ratios of EGFP+ cells were normalized by transfection efficiency.
  • FIG. 7 depicts quantification of the EGFP positive (EGFP+) cells.
  • RNA editing methods referred herein as the “improved LEAPER” methods
  • specially designed RNAs referred herein as deaminase-recruiting RNAs (“dRNAs”) or ADAR-recruiting RNAs (“arRNAs”) or constructs comprising nucleic acids encoding these dRNAs, to edit target RNAs in a host cell.
  • dRNAs deaminase-recruiting RNAs
  • arRNAs ADAR-recruiting RNAs
  • LEAPER Leveraging Endogenous ADAR for Programmable Editing on RNA
  • LEAPER method was described in PCT/CN2018/110105 and PCT/CN2020/084922, which are incorporated herein by reference in their entirety.
  • a targeting RNA that is partially complementary to the target transcript was used to recruit native ADAR1 or ADAR2 to change adenosine to inosine at a specific site in a target RNA.
  • RNA editing can be achieved in certain systems without ectopic or overexpression of the ADAR proteins in the host cell.
  • the improved LEAPER method involves use of circular dRNA or dRNA capable of forming a circular RNA.
  • the improved LEAPER method involves use of dRNA comprising one or more small nucleolar RNA (snoRNA) linked to the 3′ or 5′ of the targeting RNA sequence.
  • the improved LEAPER method involves dRNAs placed under the control of a polymerase II promoter (“Pol II promoter”).
  • Polymerase II promoter a polymerase II promoter
  • the present application in one aspect provides a method of editing a target RNA by one or more of the improved LEAPER methods.
  • dRNAs and constructs used for the improved LEAPER methods are provided.
  • RNA editing methods for treating or preventing a disease or condition in an individual using the RNA editing methods.
  • deaminase-recruiting RNA “dRNA,” “ADAR-recruiting RNA” and “arRNA” are used herein interchangeably to refer to an engineered RNA capable of recruiting an ADAR to deaminate a target adenosine in an RNA.
  • polynucleotide refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
  • nucleobases as such.
  • adenosine guanosine
  • cytidine thymidine
  • uridine uridine
  • nucleoside refers to the nucleobase linked to the ribose or deoxyribose.
  • nucleotide refers to the respective nucleobase-ribosyl-phosphate or nucleobase-deoxyribosyl-phosphate.
  • adenosine and adenine with the abbreviation, “A”
  • guanosine and guanine with the abbreviation, “G”
  • cytosine and cytidine with the abbreviation, “C”
  • uracil and uridine with the abbreviation, “U”
  • thymine and thymidine with the abbreviation, “T”
  • inosine and hypo-xanthine with the abbreviation, “I”
  • nucleobase, nucleoside and nucleotide are used interchangeably, unless the context clearly requires differently.
  • introducing means delivering one or more polynucleotides, such as dRNAs or one or more constructs including vectors as described herein, one or more transcripts thereof, to a host cell.
  • the invention serves as a basic platform for enabling targeted editing of RNA, for example, pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA (such as miRNA).
  • the methods of the present application can employ many delivery systems, including but not limited to, viral, liposome, electroporation, microinjection and conjugation, to achieve the introduction of the dRNA or construct as described herein into a host cell.
  • Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a construct described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes for delivery to the host cell.
  • target RNA refers to an RNA sequence to which a deaminase-recruiting RNA sequence is designed to have perfect complementarity or substantial complementarity, and hybridization between the target sequence and the dRNA forms a double stranded RNA (dsRNA) region containing a target adenosine, which recruits an adenosine deaminase acting on RNA (ADAR) that deaminates the target adenosine.
  • dsRNA double stranded RNA
  • ADAR adenosine deaminase acting on RNA
  • the ADAR is naturally present in a host cell, such as a eukaryotic cell (such as a mammalian cell, e.g., a human cell).
  • the ADAR is introduced into the host cell.
  • complementarity refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid by traditional Watson-Crick base-pairing.
  • a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (i.e., Watson-Crick base pairing) with a second nucleic acid (e.g., about 5, 6, 7, 8, 9, 10 out of 10, being about 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively).
  • Perfectly complementary means that all the contiguous residues of a nucleic acid sequence form hydrogen bonds with the same number of contiguous residues in a second nucleic acid sequence.
  • substantially complementary refers to a degree of complementarity that is at least about any one of 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of about 40, 50, 60, 70, 80, 100, 150, 200, 250 or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
  • stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993). Laboratory Techniques In Biochemistry And Molecular Biology—Hybridization With Nucleic Acid Probes Part I, Second Chapter “Overview of principles of hybridization and the strategy of nucleic acid probe assay,” Elsevier, N,Y.
  • Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues.
  • the hydrogen bonding may occur by Watson Crick base pairing, Hoogstein binding, or in any other sequence specific manner.
  • a sequence capable of hybridizing with a given sequence is referred to as the “complement” of the given sequence.
  • a “carrier” includes pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed.
  • the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • buffers such as phosphate, citrate, and other organic acids
  • antioxidants including ascorbic acid
  • proteins such as serum albumin,
  • an effective amount or “therapeutically effective amount” of a substance is at least the minimum concentration required to effect a measurable improvement or prevention of a particular disorder.
  • An effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the substance to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects.
  • an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation in cancer.
  • an effective amount is an amount sufficient to delay development of cancer.
  • an effective amount is an amount sufficient to prevent or delay recurrence. In some embodiments, an effective amount is an amount sufficient to reduce recurrence rate in the individual.
  • An effective amount can be administered in one or more administrations.
  • the effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; (vii) reduce recurrence rate of tumor, and/or (viii) relieve to some extent one or more of the symptoms associated with the cancer.
  • an effective amount can be administered in one or more administrations.
  • an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly.
  • an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition.
  • an “effective amount” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • a “host cell” as described herein refers to any cell type that can be used as a host cell provided it can be modified as described herein.
  • the host cell may be a host cell with endogenously expressed adenosine deaminase acting on RNA (ADAR), or may be a host cell into which an adenosine deaminase acting on RNA (ADAR) is introduced by a known method in the art.
  • the host cell may be a prokaryotic cell, a eukaryotic cell or a plant cell.
  • the host cell is derived from a pre-established cell line, such as mammalian cell lines including human cell lines or non-human cell lines.
  • the host cell is derived from an individual, such as a human individual.
  • a “recombinant AAV vector (rAAV vector)” refers to a polynucleotide vector comprising one or more heterologous sequences (i.e., nucleic acid sequence not of AAV origin) that are flanked by at least one, and in embodiments two, AAV inverted terminal repeat sequences (ITRs).
  • rAAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been infected with a suitable helper virus (or that is expressing suitable helper functions) and that is expressing AAV rep and cap gene products (i.e. AAV Rep and Cap proteins).
  • a rAAV vector When a rAAV vector is incorporated into a larger polynucleotide (e.g., in a chromosome or in another vector such as a plasmid used for cloning or transfection), then the rAAV vector may be referred to as a “pro-vector” which can be “rescued” by replication and encapsidation in the presence of AAV packaging functions and suitable helper functions.
  • An rAAV vector can be in any of a number of forms, including, but not limited to, plasmids, linear artificial chromosomes, complexed with lipids, encapsulated within liposomes, and encapsidated in a viral particle, particularly an AAV particle.
  • a rAAV vector can be packaged into an AAV virus capsid to generate a “recombinant adeno-associated viral particle (rAAV particle)”.
  • An “AAV inverted terminal repeat (ITR)” sequence is an approximately 145-nucleotide sequence that is present at both termini of the native single-stranded AAV genome.
  • the outermost 125 nucleotides of the ITR can be present in either of two alternative orientations, leading to heterogeneity between different AAV genomes and between the two ends of a single AAV genome.
  • the outermost 125 nucleotides also contains several shorter regions of self-complementarity (designated A, A′, B, B′, C, C′ and D regions), allowing intrastrand base-pairing to occur within this portion of the ITR.
  • a “package insert” refers to instructions customarily included in commercial packages of medicaments that contain information about the indications customarily included in commercial packages of medicaments that contain information about the indications, usage, dosage, administration, contraindications, other medicaments to be combined with the packaged product, and/or warnings concerning the use of such medicaments, etc.
  • a “subject,” “patient” or “individual” includes a mammal, such as a human or other animal, and typically is human.
  • the subject e.g., patient, to whom the therapeutic agents and compositions are administered, is a mammal, typically a primate, such as a human.
  • the primate is a monkey or an ape.
  • the subject can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects.
  • the subject is a non-primate mammal, such as a rodent, a dog, a cat, a farm animal, such as a cow or a horse, etc.
  • treatment refers to clinical intervention designed to have beneficial and desired effects to the natural course of the individual or cell being treated during the course of clinical pathology.
  • desirable effects of treatment include, without limitation, decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis.
  • an individual is successfully “treated” if one or more symptoms associated with cancer are mitigated or eliminated, including, but are not limited to, reducing the proliferation of (or destroying) cancerous cells, increasing cancer cell-killing, decreasing symptoms resulting from the disease, preventing spread of diseases, preventing recurrence of disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of individuals.
  • dRNA deaminase-recruiting RNA
  • a construct comprising a nucleic acid encoding the dRNA into the host cell (e.g., eukaryotic cell), wherein: (1) the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA and (2) the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • dRNA deaminase-recruiting RNA
  • ADAR adenosine deaminase acting on RNA
  • dRNA deaminase-recruiting RNA
  • a construct comprising a nucleic acid encoding the dRNA into the host cell (e.g., eukaryotic cell), wherein: (1) the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA, (2) the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and (3) the dRNA is a circular RNA or capable of forming a circular RNA.
  • ADAR adenosine deaminase acting on RNA
  • dRNA deaminase-recruiting RNA
  • the method does not comprise introducing any protein or construct comprising a nucleic acid encoding a protein (e.g., Cas, ADAR or a fusion protein of ADAR and Cas) to the host cell.
  • a protein e.g., Cas, ADAR or a fusion protein of ADAR and Cas
  • dRNA deaminase-recruiting RNA
  • the method does not comprise introducing any protein or construct comprising a nucleic acid encoding a protein (e.g., Cas, ADAR or a fusion protein of ADAR and Cas) to the host cell.
  • a protein e.g., Cas, ADAR or a fusion protein of ADAR and Cas
  • dRNA deaminase-recruiting RNA
  • the method does not comprise introducing any protein or construct comprising a nucleic acid encoding a protein (e.g., Cas, ADAR or a fusion protein of ADAR and Cas) to the host cell.
  • a protein e.g., Cas, ADAR or a fusion protein of ADAR and Cas
  • dRNA deaminase-recruiting RNA
  • ADAR a construct comprising a nucleic acid encoding the ADAR into the host cell
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting the ADAR to deaminate a target adenosine (“A”) residue in the target RNA
  • the dRNA is a circular RNA or capable of forming a circular RNA.
  • the ADAR is an endogenously encoded ADAR of the host cell, wherein introduction of the ADAR comprises over-expressing the ADAR in the host cell.
  • the ADAR is exogenous to the host cell.
  • the construct comprising a nucleic acid encoding the ADAR is a vector, such as a plasmid, or a viral vector (e.g., an AAV or a lentiviral vector).
  • the present application provides a method for editing a plurality of target RNAs (e.g., at least about 2, 3, 4, 5, 10, 20, 50, 100, 1000 or more) in host cells by introducing a plurality of the dRNAs, or one or more constructs encoding the dRNAs, into the host cells.
  • a plurality of target RNAs e.g., at least about 2, 3, 4, 5, 10, 20, 50, 100, 1000 or more
  • the dRNA is a linear RNA that is capable of forming a circular RNA.
  • the circulation is performed using the Tornado expression system (“Twister-optimized RNA for durable overexpression”) as described in Litke, J. L. & Jaffrey, S. R. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat Biotechnol 37, 667-675 (2019), which is hereby incorporated herein by reference in its entirety.
  • Tornado-expressed transcripts contain an RNA of interest flanked by Twister ribozymes.
  • a twister ribozyme is any catalytic RNA sequences that are capable of self-cleavage. The ribozymes rapidly undergo autocatalytic cleavage, leaving termini that are ligated by an RNA ligase.
  • the dRNA is introduced by a construct comprising a nucleic acid encoding the dRNA.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA.
  • the construct further comprises a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA and a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the 3′ twister sequence is twister P3 U2A and the 5′ twister sequence is twister P1. In some embodiments, wherein the 5′ twister sequence is twister P3 U2A and the 3′ twister sequence is twister P1. In some embodiments, the dRNA undergoes autocatalytic cleavage. In some embodiments, the catalyzed dRNA product comprises a 5′-hydroxyl group and a 2′,3′-cyclic phosphate at the 3′ terminus. In some embodiments, the catalyzed dRNA product is ligated by ubiquitous endogenous RNA ligase (e.g., RNA ligase RtcB). In some embodiments, the construct is a plasmid or a viral vector.
  • ubiquitous endogenous RNA ligase e.g., RNA ligase RtcB
  • the dRNA transcript is also flanked by a 5′ and/or 3′ ligation sequences, which are then flanked by the 5′-Twister ribozyme and/or 3′-Twister ribozymes, respectively.
  • the dRNA comprises a 3′ ligation sequence.
  • the dRNA comprises a 5′ ligation sequence.
  • the dRNA further comprises a 3′ ligation sequence and a 5′ ligation sequence.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least partially complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% complementary to each other. In some embodiments, the 3′ ligation sequence and the 5′ ligation sequence are fully complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are independently at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides or at least about 100 nucleotides in length.
  • the 3′ ligation sequence and the 5′ ligation sequence are independently about 20-30 nucleotides, about 30-40 nucleotides, about 40-50 nucleotides, about 50-60 nucleotides, about 60-70 nucleotides, about 70-80 nucleotides, about 80-90 nucleotides, about 90-100 nucleotides, about 100-125 nucleotides, about 125-150 nucleotides, about 20-50 nucleotides, about 50-100 nucleotides or about 100-150 nucleotides in length.
  • the dRNA is circularized by an RNA ligase.
  • RNA ligase include: RtcB, T4 RNA Ligase 1, T4 RNA Ligase 2, Rnl3 and Trl1.
  • the RNA ligase is expressed endogenously in the host cell.
  • the RNA ligase is RNA ligase RtcB.
  • the method further comprises introducing an RNA ligase (e.g., RtcB) into the host cell.
  • the dRNA is circularized before being introduced to the host cell.
  • the dRNA is chemically synthesized.
  • the dRNA is circularized through in vitro enzymatic ligation (e.g., using RNA or DNA ligase) or chemical ligation (e.g., using cyanogen bromide or a similar condensing agent).
  • a target RNA in a host cell comprising introducing a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid encoding the dRNA into the host cell, wherein the dRNA comprises: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence; and wherein the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • dRNA deaminase-recruiting RNA
  • a construct comprising a nucleic acid encoding the dRNA into the host cell
  • the dRNA comprises: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence; and
  • a target RNA in a host cell comprising introducing a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid encoding the dRNA into the host cell, wherein the dRNA comprises: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence; and wherein the dRNA is capable of recruiting an endogenously expressed adenosine deaminase acting on RNA (ADAR) of the host cell to deaminate a target adenosine residue in the target RNA.
  • the method does not comprise introducing any protein or construct comprising a nucleic acid encoding a protein (e.g., Cas, ADAR or a fusion protein of ADAR and Ca
  • a target RNA in a host cell comprising introducing (a) a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid encoding the dRNA and (b) an ADAR or a construct comprising a nucleic acid encoding the ADAR into the host cell, wherein the dRNA comprises: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence; and wherein the dRNA is capable of recruiting the ADAR to deaminate a target adenosine residue in the target RNA.
  • dRNA deaminase-recruiting RNA
  • ADAR small nucleolar RNA
  • the ADAR is an endogenously encoded ADAR of the host cell, wherein introduction of the ADAR comprises over-expressing the ADAR in the host cell.
  • the ADAR is exogenous to the host cell.
  • the construct comprising a nucleic acid encoding the ADAR is a vector, such as a plasmid, or a viral vector (e.g., an AAV or a lentiviral vector).
  • the present application provides a method for editing a plurality of target RNAs (e.g., at least about 2, 3, 4, 5, 10, 20, 50, 100, 1000 or more) in host cells by introducing a plurality of the dRNAs, or one or more constructs encoding the dRNAs, into the host cells.
  • a plurality of target RNAs e.g., at least about 2, 3, 4, 5, 10, 20, 50, 100, 1000 or more
  • Small nucleolar RNAs are small non-coding RNA molecules that are known to guide chemical modifications of other RNAs such as ribosomal RNAs, transfer RNAs, and small nuclear RNAs.
  • RNA binding proteins RBPs
  • accessory proteins RNA binding proteins
  • snoRNP small nucleolar ribonucleoprotein
  • snoRNAs include, for example, composite H/ACA and C/D box snoRNA and orphan snoRNAs.
  • the snoRNA sequence described herein can comprise a naturally-occurring snoRNA, a portion thereof, or a variant thereof.
  • the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”). In some embodiments, the dRNA comprises a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (“3′ snoRNA sequence”). In some embodiments, the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”) and a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (“3′ snoRNA sequence”).
  • the snoRNA sequence is at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, at least about 100 nucleotides, at least about 110 nucleotides, at least about 120 nucleotides, at least about 130 nucleotides, at least about 140 nucleotides, at least about 150 nucleotides, at least about 160 nucleotides, at least about 170 nucleotides, at least about 180 nucleotides, at least about 190 nucleotides or at least about 200 nucleotides in length.
  • the snoRNA sequence is about 50-75 nucleotides, about 75-100 nucleotides, about 100-125 nucleotides, about 125-150 nucleotides, about 150-175 nucleotides, about 175-200 nucleotides, about 50-100 nucleotides, about 100-150 nucleotides, about 150-200 nucleotides, about 125-175 nucleotides, or about 100-200 nucleotides in length.
  • the 3′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 1 (5′-AAGATTGTGTGTGGATCGATGATGACTTCCATATATACATTCCTTGGAAAGCTGAAC AAAATGAGTGAAAACTCTATACCGTCATTCTCGTCGAACTGAGGTCCAGCACATTAC TCCAACAG-3′).
  • the 5′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 2 (5′-GAGTGAGATCTTGGACCAATGATGACTTCCATACATGCATTCCTTGGAAAGCTGAAC AAAATGAGTGGGAACTCTGTACTATCATCTTAGTTGAACTGAGGTCCACCGGGGGCT AA-3′).
  • the snoRNA sequence is a C/D Box snoRNA sequence. In some embodiments, the snoRNA sequence is an H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is a composite C/D Box and H/ACA Box snoRNA sequence. In some embodiments, the snoRNA sequence is an orphan snoRNA sequence.
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR)
  • the construct comprises a polymerase 11 promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an endogenously expressed adenosine deaminase acting on RNA (ADAR) of the host cell to deaminate a target adenosine residue in the target RNA
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • the method does not comprise introducing any protein or construct comprising a nucleic acid encoding a protein (e.g., Cas, ADAR or a fusion protein of ADAR and Cas) to the host cell.
  • RNA deaminase-recruiting RNA
  • ADAR an ADAR or a construct comprising a nucleic acid encoding the ADAR
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting the adenosine deaminase acting on RNA (ADAR) to deaminate a target adenosine residue in the target RNA
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • the ADAR is an endogenously encoded ADAR of the host cell, wherein introduction of the ADAR comprises over-expressing the ADAR in the host cell.
  • the ADAR is exogenous to the host cell.
  • the construct comprising a nucleic acid encoding the ADAR is a vector, such as a plasmid, or a viral vector (e.g., an AAV or a lentiviral vector).
  • the present application provides a method for editing a plurality of target RNAs (e.g., at least about 2, 3, 4, 5, 10, 20, 50, 100, 1000 or more) in host cells by introducing a plurality of the dRNAs, or one or more constructs encoding the dRNAs, into the host cells.
  • one Pol II promoter e.g., CMV
  • Non-limiting examples of Pol II promoters include: CMV, SV40, EF-1 ⁇ , CAG and RSV.
  • the Pol II promoter is a CMV promoter.
  • the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 3 (5′-CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCC ATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTG ACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA TCATATGCCAAGTACGCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCA TTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTA GTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAG CGGTTTGACTCACGGGGATTTCCAAG
  • the host cell is a prokaryotic cell. In some embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is a mammalian cell. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a murine cell. In some embodiments, the host cell is a plant cell or a fungal cell.
  • the host cell is a cell line, such as HEK293T, HT29, A549, HepG2, RD, SF268, SW13 and HeLa cell.
  • the host cell is a primary cell, such as fibroblast, epithelial, or immune cell.
  • the host cell is a T cell.
  • the host cell is a post-mitosis cell.
  • the host cell is a cell of the central nervous system (CNS), such as a brain cell, e.g., a cerebellum cell.
  • CNS central nervous system
  • the ADAR is endogenous to the host cell.
  • the adenosine deaminase acting on RNA (ADAR) is naturally or endogenously present in the host cell, for example, naturally or endogenously present in the eukaryotic cell.
  • the ADAR is endogenously expressed by the host cell.
  • the ADAR is exogenously introduced into the host cell.
  • the ADAR is ADAR1 and/or ADAR2.
  • the ADAR is one or more ADARs selected from the group consisting of hADAR1, hADAR2, mouse ADAR1 and ADAR2.
  • the ADAR is ADAR1, such as p110 isoform of ADAR1 (“ADAR1 p110 ”) and/or p150 isoform of ADAR1 (“ADAR1 p150 ”).
  • the ADAR is ADAR2.
  • the ADAR is an ADAR2 expressed by the host cell, e.g., ADAR2 expressed by cerebellum cells.
  • the ADAR is an ADAR exogenous to the host cell. In some embodiments, the ADAR is a hyperactive mutant of a naturally occurring ADAR. In some embodiments, the ADAR is ADAR1 comprising an E1008Q mutation. In some embodiments, the ADAR is not a fusion protein comprising a binding domain. In some embodiments, the ADAR does not comprise an engineered double-strand nucleic acid-binding domain. In some embodiments, the ADAR does not comprise a MCP domain that binds to MS2 hairpin that is fused to the complementary RNA sequence in the dRNA. In some embodiments, the ADAR does not comprise a DSB.
  • the host cell has high expression level of ADAR1 (such as ADAR1 p110 and/or ADAR1 p150 ), e.g., at least about any one of 10%, 20%, 50%, 100%, 2 ⁇ , 3 ⁇ , 5 ⁇ , or more relative to the protein expression level of ⁇ -tubulin.
  • the host cell has high expression level of ADAR2, e.g., at least about any one of 10%, 20%, 50%, 100%, 2 ⁇ , 3 ⁇ , 5 ⁇ , or more relative to the protein expression level of ⁇ -tubulin.
  • the host cell has low expression level of ADAR3, e.g., no more than about any one of 5 ⁇ , 3 ⁇ , 2 ⁇ , 100%, 50%, 20% or less relative to the protein expression level of ⁇ -tubulin.
  • the dRNA comprises at least about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nucleotides. In certain embodiments according to any one of the methods described herein, the dRNA comprises no more than about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nucleotides.
  • the dRNA is about any one of 40-260, 45-250, 50-240, 60-230, 65-220, 70-220, 70-210, 70-200, 70-190, 70-180, 70-170, 70-160, 70-150, 70-140, 70-130, 70-120, 70-110, 70-100, 70-90, 70-80, 75-200, 80-190, 85-180, 90-170, 95-160, 100-200, 100-150, 100-175, 110-200, 110-175, 110-150, or 105-140 nucleotides in length.
  • the dRNA does not comprise an ADAR-recruiting domain.
  • ADAR-recruiting domain can be a nucleotide sequence or structure that binds at high affinity to ADAR, or a nucleotide sequence that binds to a binding partner fused to ADAR in an engineered ADAR construct.
  • ADAR-recruiting domains include, but are not limited to, GluR-2, GluR-B (R/G), GluR-B (Q/R), GluR-6 (R/G), 5HT2C, and FlnA (Q/R) domain; see, for example, Wahlstedt, Helene, and Marie, “Site-selective versus promiscuous A-to-I editing.” Wiley Interdisciplinary Reviews: RNA 2.6 (2011): 761-771, which is incorporated herein by reference in its entirety.
  • the dRNA does not comprise a double-stranded portion.
  • the dRNA does not comprise a hairpin, such as MS2 stem loop.
  • the dRNA is single stranded. In some embodiments, the dRNA does not comprise a DSB-binding domain. In some embodiments, the dRNA consists of (or consists essentially of) the complementary RNA sequence.
  • the dRNA does not comprise chemical modifications.
  • the dRNA does not comprise a chemically modified nucleotide, such as 2′-O-methyl nucleotide or a nucleotide having a phosphorothioate linkage.
  • the dRNA comprises 2′-O-methyl and phosphorothioate linkage modifications only at the first three and last three residues.
  • the dRNA is not an antisense oligonucleotide (ASO).
  • the dRNAs described herein comprise a targeting RNA sequence that is at least partially complementary to the target RNA.
  • the targeting RNA sequence in the dRNA comprises at least about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nucleotides.
  • the targeting RNA sequence in the dRNA comprises no more than about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nucleotides.
  • the targeting RNA sequence in the dRNA is about anyone of 40-260, 45-250, 50-240, 60-230, 65-220, 70-220, 70-210, 70-200, 70-190, 70-180, 70-170, 70-160, 70-150, 70-140, 70-130, 70-120, 70-110, 70-100, 70-90, 70-80, 75-200, 80-190, 85-180, 90-170, 95-160, 100-200, 100-150, 100-175, 110-200, 110-160, 110-175, 110-150, 140-160, 105-140, or 105-155 nucleotides in length.
  • the targeting RNA sequence in the dRNA is about 71 nucleotides long. In some embodiments, the dRNA is about 111 nucleotides long. In some embodiments, the dRNA is about 151 nucleotides long.
  • the targeting RNA sequence comprises a cytidine, adenosine or uridine directly opposite the target adenosine residue in the target RNA. In some embodiments, the targeting RNA sequence comprises a cytidine mismatch directly opposite the target adenosine residue in the target RNA. In some embodiments, the cytidine mismatch is located at least 5 nucleotides, e.g., at least 10, 15, 20, 25, 30, or more nucleotides, away from the 5′ end of the targeting RNA sequence.
  • the cytidine mismatch is located at least 20 nucleotides, e.g., at least 25, 30, 35, or more nucleotides, away from the 3′ end of the complementary RNA sequence. In some embodiments, the cytidine mismatch is not located within 20 (e.g., 15, 10, 5 or fewer) nucleotides away from the 3′ end of the targeting RNA sequence.
  • the cytidine mismatch is located at least 20 nucleotides (e.g., at least 25, 30, 35, or more nucleotides) away from the 3′ end and at least 5 nucleotides (e.g., at least 10, 15, 20, 25, 30, or more nucleotides) away from the 5′ end of the targeting RNA sequence.
  • the cytidine mismatch is located in the center of the targeting RNA sequence. In some embodiments, the cytidine mismatch is located within 20 nucleotides (e.g., 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotide) of the center of the targeting sequence in the dRNA.
  • the targeting RNA sequence further comprises one or more guanosine(s), such as 1, 2, 3, 4, 5, 6, or more Gs, that is each directly opposite a non-target adenosine in the target RNA.
  • the targeting RNA sequence comprises two or more consecutive mismatch nucleotides (e.g., 2, 3, 4, 5, or more mismatch nucleotides) opposite a non-target adenosine in the target RNA.
  • the target RNA comprises no more than about 20 non-target As, such as no more than about any one of 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-target A.
  • the Gs and consecutive mismatch nucleotides opposite non-target As may reduce off-target editing effects by ADAR.
  • the 5′ nearest neighbor of the target adenosine residue is a nucleotide selected from U, C, A and G with the preference U>C ⁇ A>G and the 3′ nearest neighbor of the target adenosine residue is a nucleotide selected from G, C. A and U with the preference G>C>A ⁇ U.
  • the target adenosine residue is in a three-base motif selected from the group consisting of UAG, UAC, UAA, UAU, CAG, CAC, CAA, CAU, AAG, AAC, AAA, AAU, GAG, GAC, GAA and GAU in the target RNA.
  • the three-base motif is UAG
  • the dRNA comprises an A directly opposite the U in the three-base motif, a C directly opposite the target A, and a C, G or U directly opposite the G in the three-base motif.
  • the three-base motif is UAG in the target RNA
  • the dRNA comprises ACC, ACG or ACU that is opposite the UAG of the target RNA.
  • the three-base motif is UAG in the target RNA, and the dRNA comprises ACC that is opposite the UAG of the target RNA.
  • the target RNA is any one selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA (e.g., miRNA).
  • the target RNA is a pre-messenger RNA.
  • the target RNA is a messenger RNA.
  • the method further comprises introducing an inhibitor of ADAR3 to the host cell.
  • the inhibitor of ADAR3 is an RNAi against ADAR3, such as a shRNA against ADAR3 or a siRNA against ADAR3.
  • the method further comprises introducing a stimulator of interferon to the host cell.
  • the ADAR is inducible by interferon, for example, the ADAR is ADAR p150 .
  • the stimulator of interferon is IFN ⁇ .
  • the inhibitor of ADAR3 and/or the stimulator of interferon are encoded by the same construct (e.g., vector) that encodes the dRNA.
  • the efficiency of editing of the target RNA is at least about 10%, such as at least about any one of 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or higher. In some embodiments, the efficiency of editing of the target RNA is at least about 40%. In some embodiments, the efficiency of editing is determined by Sanger sequencing. In some embodiments, the efficiency of editing is determined by next-generation sequencing. In some embodiments, the efficiency of editing is determined by assessing expression of a reporter gene, such as a fluorescence reporter, e.g., EGFP.
  • a reporter gene such as a fluorescence reporter, e.g., EGFP.
  • the method has low off-target editing rate. In some embodiments, the method has lower than about 1% (e.g., no more than about any one of 0.5%, 0.1%, 0.05%, 0.01%, 0.001% or lower) editing efficiency on non-target As in the target RNA. In some embodiments, the method does not edit non-target As in the target RNA. In some embodiments, the method has lower than about 0.1% (e.g., no more than about any one of 0.05%, 0.01%, 0.005%, 0.001%, 0.0001% or lower) editing efficiency on As in non-target RNA.
  • the method does not induce immune response, such as innate immune response. In some embodiments, the method does not induce interferon and/or interleukin expression in the host cell. In some embodiments, the method does not induce IFN- ⁇ and/or IL-6 expression in the host cell.
  • edited RNA or host cells having an edited RNA produced by any one of the methods described herein comprises an inosine.
  • the host cell comprises an RNA having a missense mutation, an early stop codon, an alternative splice site, or an aberrant splice site.
  • the host cell comprises a mutant, truncated, or misfolded protein.
  • Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid: nucleic acid conjugates, electroporation, nanoparticles, exosomes, microvesicles, or gene-gun, naked DNA and artificial virions.
  • RNA or DNA viral based systems for the delivery of nucleic acids has high efficiency in targeting a virus to specific cells and trafficking the viral payload to the cellular nuclei.
  • the method comprises introducing a viral vector (such as an AAV or a lentiviral vector) encoding the dRNA to the host cell.
  • a viral vector such as an AAV or a lentiviral vector
  • the vector is a recombinant adeno-associated virus (rAAV) vector.
  • the construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences. In some embodiments, the construct is flanked by two AAV ITRs.
  • the AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITRs.
  • the AAV ITRs are AAV2 ITRs.
  • the vector further comprises a stuffer nucleic acid.
  • the stuffer nucleic acid is located upstream or downstream of the nucleic acid encoding the dRNA.
  • the vector is a self-complementary rAAV vector.
  • the vector comprises first nucleic acid sequence encoding the dRNA and a second nucleic acid sequence encoding a complement of the dRNA, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.
  • the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.
  • the vector is encapsidated in a rAAV particle.
  • the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV, or rAAV2/HBoV1 serotype capsid.
  • the method comprises introducing a plasmid encoding the dRNA to the host cell.
  • the method comprises electroporation of the dRNA (e.g., synthetic dRNA) into the host cell.
  • the method comprises transfection of the dRNA into the host cell.
  • modification of the target RNA and/or the protein encoded by the target RNA can be determined using different methods depending on the positions of the targeted adenosines in the target RNA. For example, in order to determine whether “A” has been edited to “I” in the target RNA, RNA sequencing methods known in the art can be used to detect the modification of the RNA sequence.
  • the RNA editing may cause changes to the amino acid sequence encoded by the mRNA. For example, point mutations may be introduced to the mRNA of an innate or acquired point mutation in the mRNA may be reversed to yield wild-type gene product(s) because of the conversion of “A” to “1”.
  • Amino acid sequencing by methods known in the art can be used to find any changes of amino acid residues in the encoded protein.
  • Modifications of a stop codon may be determined by assessing the presence of a functional, elongated, truncated, full-length and/or wild-type protein. For example, when the target adenosine is located in a UGA, UAG, or UAA stop codon, modification of the target adenosine residue (UGA or UAG) or As (UAA) may create a read-through mutation and/or an elongated protein, or a truncated protein encoded by the target RNA may be reversed to create a functional, full-length and/or wild-type protein.
  • Editing of a target RNA may also generate an aberrant splice site, and/or alternative splice site in the target RNA, thus leading to an elongated, truncated, or misfolded protein, or an aberrant splicing or alternative splicing site encoded in the target RNA may be reversed to create a functional, correctly-folding, full-length and/or wild-type protein.
  • the present application contemplates editing of both innate and acquired genetic changes, for example, missense mutation, early stop codon, aberrant splicing or alternative splicing site encoded by a target RNA. Using known methods to assess the function of the protein encoded by the target RNA can find out whether the RNA editing achieves the desired effects.
  • identification of the deamination into inosine may provide assessment on whether a functional protein is present, or whether a disease or drug resistance-associated RNA caused by the presence of a mutated adenosine is reversed or partly reversed.
  • identification of the deamination into inosine may provide a functional indication for identifying a cause of disease or a relevant factor of a disease.
  • the read-out may be the assessment of occurrence and frequency of aberrant splicing.
  • the deamination of a target adenosine is desirable to introduce a splice site, then similar approaches can be used to check whether the required type of splicing occurs.
  • An exemplary suitable method to identify the presence of an inosine after deamination of the target adenosine is RT-PCR and sequencing, using methods that are well-known to the person skilled in the art.
  • the effects of deamination of target adenosine(s) include, for example, point mutation, early stop codon, aberrant splice site, alternative splice site and misfolding of the resulting protein. These effects may induce structural and functional changes of RNAs and/or proteins associated with diseases, whether they are genetically inherited or caused by acquired genetic mutations, or may induce structural and functional changes of RNAs and/or proteins associated with occurrence of drug resistance.
  • the dRNAs, the constructs encoding the dRNAs, and the RNA editing methods of present application can be used in prevention or treatment of hereditary genetic diseases or conditions, or diseases or conditions associated with acquired genetic mutations by changing the structure and/or function of the disease-associated RNAs and/or proteins.
  • the target RNA is a regulatory RNA.
  • the target RNA to be edited is a ribosomal RNA, a transfer RNA, a long non-coding RNA or a small RNA (e.g., miRNA, pri-miRNA, pre-miRNA, piRNA, siRNA, snoRNA, snRNA, exRNA or scaRNA).
  • the effects of deamination of the target adenosines include, for example, structural and functional changes of the ribosomal RNA, transfer RNA, long non-coding RNA or small RNA (e.g., miRNA), including changes of three-dimensional structure and/or loss of function or gain of function of the target RNA.
  • deamination of the target As in the target RNA changes the expression level of one or more downstream molecules (e.g., protein, RNA and/or metabolites) of the target RNA. Changes of the expression level of the downstream molecules can be increase or decrease in the expression level.
  • downstream molecules e.g., protein, RNA and/or metabolites
  • Some embodiments of the present application involve multiplex editing of target RNAs in host cells, which are useful for screening different variants of a target gene or different genes in the host cells.
  • the method comprises introducing a plurality of dRNAs to the host cells, at least two of the dRNAs of the plurality of dRNAs have different sequences and/or have different target RNAs.
  • each dRNA has a different sequence and/or different target RNA.
  • the method generates a plurality (e.g., at least 2, 3, 5, 10, 50, 100, 1000 or more) of modifications in a single target RNA in the host cells.
  • the method generates a modification in a plurality (e.g., at least 2, 3, 5, 10, 50, 100, 1000 or more) of target RNAs in the host cells.
  • the method comprises editing a plurality of target RNAs in a plurality of populations of host cells.
  • each population of host cells receive a different dRNA or a dRNAs having a different target RNA from the other populations of host cells.
  • RNAs or constructs useful for any one of the methods described herein. Any one of the dRNAs or constructs described in this section may be used in the methods of RNA editing and treatment described herein. It is intended that any of the features and parameters described herein for dRNAs or constructs can be combined with each other, as if each and every combination is individually described.
  • the dRNAs described herein do not comprise a tracrRNA, crRNA or gRNA used in a CRISPR/Cas system.
  • a deaminase-recruiting RNA for deamination of a target adenosine in a target RNA by recruiting an ADAR, comprising a complementary RNA sequence that hybridizes to the target RNA.
  • the present provides a construct comprising any one of the deaminase-recruiting RNAs described herein.
  • the construct is a viral vector (such as a lentivirus vector) or a plasmid.
  • the construct encodes a single dRNA.
  • the construct encodes a plurality (e.g., about any one of 1, 2, 3, 4, 5, 10, 20 or more) dRNAs.
  • the present application provides a library comprising a plurality of the deaminase-recruiting RNAs or a plurality of the constructs described herein.
  • the present application provides a composition or a host cell comprising the deaminase-recruiting RNA or the construct described herein.
  • the host cell is a prokaryotic cell or a eukaryotic cell.
  • the host cell is a mammalian cell. In some embodiments, the host cell is a human cell.
  • a deaminase-recruiting RNAs for editing a target RNA comprising a targeting RNA sequence that is at least partially complementary to the target RNA, wherein the dRNA is capable of recruiting an Adenosine Deaminase Acting on RNA (ADAR), and wherein the dRNA is circular or is capable of forming a circular RNA.
  • dRNA deaminase-recruiting RNAs
  • the dRNA is a linear RNA that is capable of forming a circular RNA.
  • the dRNA is circulated by the Tornado method.
  • the dRNA transcript is also flanked by a 5′ and/or 3′ ligation sequences which are then flanked by the 5′-Twister ribozyme and/or 3′-Twister ribozymes, respectively.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least partially complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90°/%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% complementary to each other. In some embodiments, the 3′ ligation sequence and the 5′ ligation sequence are fully complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are independently at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides or at least about 100 nucleotides in length.
  • the 3′ ligation sequence and the 5′ ligation sequence are independently about 20-30 nucleotides, about 30-40 nucleotides, about 40-50 nucleotides, about 50-60 nucleotides, about 60-70 nucleotides, about 70-80 nucleotides, about 80-90 nucleotides, about 90-100 nucleotides, about 100-125 nucleotides, about 125-150 nucleotides, about 20-50 nucleotides, about 50-100 nucleotides or about 100-150 nucleotides in length.
  • the dRNA is circularized by an RNA ligase.
  • the RNA ligase is expressed endogenously in the host cell.
  • the RNA ligase is RNA ligase RtcB.
  • the RNA ligase RtcB is expressed endogenously in the host cell.
  • the dRNA is circularized through in vitro enzymatic ligation (e.g., using RNA or DNA ligase) or chemical ligation (e.g., using cyanogen bromide or a similar condensing agent).
  • a construct comprising a nucleic acid encoding the dRNA.
  • the dRNA is introduced by a construct comprising a nucleic acid encoding the dRNA.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA.
  • the construct further comprises a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA and a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the 3′ twister sequence is twister P3 U2A and the 5′ twister sequence is twister P1.
  • the 5′ twister sequence is twister P3 U2A and the 3′ twister sequence is twister P1.
  • the dRNA undergoes autocatalytic cleavage.
  • the catalyzed dRNA product comprises a 5′-hydroxyl group and a 2′,3′-cyclic phosphate at the 3′ terminus.
  • the catalyzed dRNA product is ligated by ubiquitous endogenous RNA ligase (e.g., RNA ligase RtcB).
  • the construct is a plasmid or a viral vector.
  • a deaminase-recruiting RNA (dRNA) for editing a target RNA comprising: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence at the 3′ and/or 5′ ends of the targeting RNA sequence; wherein the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • dRNA deaminase-recruiting RNA for editing a target RNA comprising: (1) a targeting RNA sequence that is at least partially complementary to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence at the 3′ and/or 5′ ends of the targeting RNA sequence; wherein the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • ADAR adenosine deaminase acting on RNA
  • the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”). In some embodiments, the dRNA comprises a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (“3′ snoRNA sequence”).
  • the snoRNA sequence is at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, at least about 100 nucleotides, at least about 110 nucleotides, at least about 120 nucleotides, at least about 130 nucleotides, at least about 140 nucleotides, at least about 150 nucleotides, at least about 160 nucleotides, at least about 170 nucleotides, at least about 180 nucleotides, at least about 190 nucleotides or at least about 200 nucleotides in length.”).
  • the snoRNA sequence is about 50-75 nucleotides, about 75-100 nucleotides, about 100-125 nucleotides, about 125-150 nucleotides, about 150-175 nucleotides, about 175-200 nucleotides, about 50-100 nucleotides, about 100-150 nucleotides, about 150-200 nucleotides, about 125-175 nucleotides, or about 100-200 nucleotides in length.
  • the 3′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 1.
  • the 5′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 2.
  • the snoRNA sequence is a C/D Box snoRNA sequence.
  • the snoRNA sequence is an H/ACA Box snoRNA sequence.
  • the snoRNA sequence is a composite C/D Box and H/ACA Box snoRNA sequence.
  • the snoRNA sequence is an orphan snoRNA sequence.
  • a construct comprising a nucleic acid encoding a deaminase-recruiting RNA (dRNA) into the host cell, wherein: (1) the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA, (2) the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and (3) the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • dRNA deaminase-recruiting RNA
  • the Pol II promoter that is operably linked to the coding nucleotide sequence, such that the promoter controls the transcription or expression of the coding nucleotide sequence.
  • the Pol II promoter may be positioned 5′ (upstream) of a coding nucleotide sequence under its control.
  • the distance between the Pol II promoter and the coding sequence may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function.
  • the construct comprises a 5′ UTR and/or a 3′UTR that regulates the transcription or expression of the coding nucleotide sequence.
  • the Pol II promoter is a CMV promoter.
  • the CMV promoter comprises the nucleic acid sequence of SEQ ID NO: 3.
  • one Pol II promoter e.g., CMV is driving expression of two or more dRNAs.
  • the targeting RNA sequence comprises a cytidine, adenosine or uridine directly opposite the target adenosine to be edited in the target RNA.
  • the targeting RNA sequence further comprises one or more guanosine(s) that is each directly opposite a non-target adenosine in the target RNA.
  • the 5′ nearest neighbor of the target adenosine residue is a nucleotide selected from U, C, A and G with the preference U>C ⁇ A>G and the 3′ nearest neighbor of the target adenosine residue is a nucleotide selected from G, C, A and U with the preference G>C>A ⁇ U.
  • the 5′ nearest neighbor of the target adenosine residue is U.
  • the 5′ nearest neighbor of the target adenosine residue is C or A.
  • the 3′ nearest neighbor of the target adenosine residue is G.
  • the 3′ nearest neighbor of the target adenosine residue is C.
  • the target adenosine residue is in a three-base motif selected from the group consisting of UAG, UAC, UAA, UAU, CAG, CAC, CAA, CAU, AAG, AAC, AAA, AAU, GAG, GAC, GAA and GAU in the target RNA.
  • the three-base motif is UAG
  • the dRNA comprises an A directly opposite the U in the three-base motif, a C directly opposite the target A, and a C, G or U directly opposite the G in the three-base motif.
  • the three-base motif is UAG in the target RNA, and the dRNA comprises ACC, ACG or ACU that is opposite the UAG of the target RNA.
  • the dRNA comprises a cytidine mismatch directly opposite the target adenosine residue in the target RNA.
  • the cytidine mismatch is close to the center of the complementary RNA sequence, such as within 20, 15, 10, 5, 4, 3, 2, or 1 nucleotide away from the center of the complementary RNA sequence.
  • the cytidine mismatch is at least 5 nucleotides away from the 5′ end of the complementary RNA sequence.
  • the cytidine mismatch is at least 20 nucleotides away from the 3′ end of the complementary RNA sequence.
  • the dRNA comprises more than about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nucleotides.
  • the dRNA is about any one of 40-260, 45-250, 50-240, 60-230, 65-220, 70-210, 70-200, 70-190, 70-180, 70-170, 70-160, 70-150, 70-140, 70-130, 70-120, 70-110, 70-100, 70-90, 70-80, 75-200, 80-190, 85-180, 90-170, 95-160, 100-150 or 105-140 nucleotides in length.
  • the dRNA of the present application comprises a targeting RNA sequence that hybridizes to the target RNA.
  • the targeting RNA sequence is perfectly complementary or substantially complementarity to the target RNA to allow hybridization of the targeting RNA sequence to the target RNA.
  • the targeting RNA sequence has 100% sequence complementarity as the target RNA.
  • the targeting RNA sequence is at least about any one of 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more complementary to over a continuous stretch of at least about any one of 20, 40, 60, 80, 100, 150, 200, or more nucleotides in the target RNA.
  • the dsRNA formed by hybridization between the targeting RNA sequence and the target RNA has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) non-Watson-Crick base pairs (i.e., mismatches).
  • ADAR for example, human ADAR enzymes edit double stranded RNA (dsRNA) structures with varying specificity, depending on a number of factors.
  • dsRNA double stranded RNA
  • One important factor is the degree of complementarity of the two strands making up the dsRNA sequence.
  • Perfect complementarity of between the dRNA and the target RNA usually causes the catalytic domain of ADAR to deaminate adenosines in a non-discriminative manner.
  • the specificity and efficiency of ADAR can be modified by introducing mismatches in the dsRNA region. For example, A-C mismatch is preferably recommended to increase the specificity and efficiency of deamination of the adenosine to be edited.
  • the G-A mismatch can reduce off-target editing.
  • Perfect complementarity is not necessarily required for a dsRNA formation between the dRNA and its target RNA, provided there is substantial complementarity for hybridization and formation of the dsRNA between the dRNA and the target RNA.
  • the dRNA sequence or single-stranded RNA region thereof has at least about any one of 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of sequence complementarity to the target RNA, when optimally aligned.
  • Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wimsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner).
  • any suitable algorithm for aligning sequences non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wimsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner).
  • the nucleotides neighboring the target adenosine also affect the specificity and efficiency of deamination.
  • the 5′ nearest neighbor of the target adenosine to be edited in the target RNA sequence has the preference U>C ⁇ A>G and the 3′ nearest neighbor of the target adenosine to be edited in the target RNA sequence has the preference G>C>A ⁇ U in terms of specificity and efficiency of deamination of adenosine.
  • the target adenosine when the target adenosine may be in a three-base motif selected from the group consisting of UAG, UAC, UAA, UAU, CAG, CAC, CAA, CAU, AAG, AAC, AAA, AAU, GAG, GAC, GAA and GAU in the target RNA, the specificity and efficiency of deamination of adenosine are higher than adenosines in other three-base motifs.
  • the target adenosine to be edited is in the three-base motif UAG, UAC, UAA, UAU, CAG, CAC, AAG, AAC or AAA
  • the efficiency of deamination of adenosine is much higher than adenosines in other motifs.
  • different designs of dRNA may also lead to different deamination efficiency.
  • the dRNA comprises cytidine (C) directly opposite the target adenosine to be edited, adenosine (A) directly opposite the uridine, and cytidine (C), guanosine (G) or uridine (U) directly opposite the guanosine
  • the efficiency of deamination of the target adenosine is higher than that using other dRNA sequences.
  • the editing efficiency of the A in the UAG of the target RNA may reach about 25%-90% (e.g., about 25%-80%, 25%-70%, 25%-60%, 25%-50%, 25%-40%, or 25%-30%).
  • dRNAs can be designed to comprise one or more guanosines directly opposite one or more adenosine(s) other than the target adenosine to be edited in the target RNA.
  • mismatch refers to opposing nucleotides in a double stranded RNA (dsRNA) which do not form perfect base pairs according to the Watson-Crick base pairing rules. Mismatch base pairs include, for example, G-A, C-A, U-C, A-A, G-G, C-C, U-U base pairs.
  • a dRNA is designed to comprise a C opposite the A to be edited, generating an A-C mismatch in the dsRNA formed by hybridization between the target RNA and dRNA.
  • the dsRNA formed by hybridization between the dRNA and the target RNA does not comprise a mismatch.
  • the dsRNA formed by hybridization between the dRNA and the target RNA comprises one or more, such as any one of 1, 2, 3, 4, 5, 6, 7 or more mismatches (e.g., the same type of different types of mismatches).
  • the dsRNA formed by hybridization between the dRNA and the target RNA comprises one or more kinds of mismatches, for example, 1, 2, 3, 4, 5, 6, 7 kinds of mismatches selected from the group consisting of G-A, C-A, U-C, A-A, G-G, C-C and U-U.
  • the mismatch nucleotides in the dsRNA formed by hybridization between the dRNA and the target RNA can form bulges, which can promote the efficiency of editing of the target RNA.
  • the additional bulge-inducing mismatches may be upstream and/or downstream of the target adenosine.
  • the bulges may be single-mismatch bulges (caused by one mismatching base pair) or multi-mismatch bulges (caused by more than one consecutive mismatching base pairs, e.g., two or three consecutive mismatching base pairs).
  • the targeting RNA sequence in the dRNA is single-stranded.
  • the dRNA may be entirely single-stranded or have one or more (e.g., 1, 2, 3, or more) double-stranded regions and/or one or more stem loop regions.
  • the targeting RNA sequence is at least about any one of 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 or more nucleotides.
  • the targeting RNA sequence is about any one of 40-260, 45-250, 50-240, 60-230, 65-220, 70-220, 70-210, 70-200, 70-190, 70-180, 70-170, 70-160, 70-150, 70-140, 70-130, 70-120, 70-110, 70-100, 70-90, 70-80, 75-200, 80-190, 85-180, 90-170, 95-160, 100-200, 100-150, 100-175, 110-200, 110-160, 110-175, 110-150, 140-160, 105-140, or 105-155 nucleotides in length.
  • the targeting RNA sequence in the dRNA is about 71 nucleotides long.
  • the dRNA is about 111 nucleotides long.
  • the dRNA is about 151 nucleotides long.
  • the dRNA apart from the targeting RNA sequence, further comprises regions for stabilizing the dRNA, for example, one or more double-stranded regions and/or stem loop regions.
  • the double-stranded region or stem loop region of the dRNA comprises no more than about any one of 200, 150, 100, 50, 40, 30, 20, 10 or fewer base-pairs.
  • the dRNA does not comprise a stem loop or double-stranded region.
  • the dRNA comprises an ADAR-recruiting domain. In some embodiments, the dRNA does not comprise an ADAR-recruiting domain.
  • the dRNA may comprise one or more modifications.
  • the dRNA has one or more modified nucleotides, including nucleobase modification and/or backbone modification.
  • modified nucleotides including nucleobase modification and/or backbone modification.
  • Exemplary modifications to the RNA include, but are not limited to, phosphorothioate backbone modification, 2′-substitutions in the ribose (such as 2′-O-methyl and 2′-fluoro substitutions), LNA, and L-RNA.
  • the dRNA does not have modifications to the nucleobase or backbone.
  • construct comprising the dRNA described herein, including, but not limited to, any of the constructs described in the sections above.
  • construct refers to DNA or RNA molecules that comprise a coding nucleotide sequence that can be transcribed into RNAs or expressed into proteins.
  • the construct contains one or more regulatory elements operably linked to the nucleotide sequence encoding the RNA or protein.
  • the construct comprises a promoter that is operably linked to the coding nucleotide sequence, such that the promoter controls the transcription or expression of the coding nucleotide sequence.
  • a promoter may be positioned 5′ (upstream) of a coding nucleotide sequence under its control. The distance between the promoter and the coding sequence may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function.
  • the construct comprises a 5′ UTR and/or a 3′UTR that regulates the transcription or expression of the coding nucleotide sequence.
  • the promoter is a U6 promoter.
  • the promoter is a Poly II promoter as discussed in the sections described above.
  • the construct is a vector encoding any one of the dRNAs disclosed in the present application.
  • the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
  • vectors refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • Other vectors e.g., non-episomal mammalian vectors
  • certain vectors are capable of directing the transcription or expression of coding nucleotide sequences to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.
  • Recombinant expression vectors can comprise a nucleic acid of the present application in a form suitable for transcription or expression of the nucleic acid in a host cell.
  • the recombinant expression vector includes one or more regulatory elements, which may be selected on the basis of the host cells to be used for transcription or expression, which is operatively linked to the nucleic acid sequence to be transcribed or expressed.
  • “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
  • the vector is a rAAV vector.
  • the rAAV vector is a vector derived from an AAV serotype, including without limitation, AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV capsid serotype or the like.
  • the nucleic acid in the AAV comprises an ITR of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV capsid serotype or the like.
  • the nucleic acid in the AAV further encodes a dRNA as described herein. Use of any AAV serotype is considered within the scope of the present disclosure.
  • the vector is encapsidated in a rAAV particle.
  • the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, AAV2-HBKO, AAVDJ8, AAVPHP.B, AAVPHP.eB, AAVBR1, AAVHSC15, AAVHSC17, goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV, or rAAV2/HBoV1 serotype capsid.
  • a construct comprising a nucleotide sequence encoding the dRNA.
  • a construct comprising a nucleotide sequence encoding the ADAR.
  • a construct comprising a first nucleotide sequence encoding the dRNA and a second nucleotide sequence encoding the ADAR.
  • the first nucleotide sequence and the second nucleotide sequence are operably linked to the same promoter.
  • the first nucleotide sequence and the second nucleotide sequence are operably linked to different promoters.
  • the promoter is inducible.
  • the construct does not encode for the ADAR.
  • the vector further comprises nucleic acid sequence(s) encoding an inhibitor of ADAR3 (e.g., ADAR3 shRNA or siRNA) and/or a stimulator of interferon (e.g., IFN- ⁇ ).
  • RNA editing methods and compositions described herein may be used to treat or prevent a disease or condition in an individual, including, but not limited to hereditary genetic diseases and drug resistance.
  • a method of editing a target RNA in a cell of an individual comprising editing the target RNA using any one of the methods of RNA editing described herein.
  • a method of editing a target RNA in a cell of an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into the cell of the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a method of editing a target RNA in a cell of an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into the cell of the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a method of editing a target RNA in a cell of an individual comprising introducing a construct comprising a nucleic acid encoding a dRNA into the cell of the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • the ADAR is endogenously expressed.
  • the method further comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR into the cell.
  • the target RNA is associated with a disease or condition of the individual.
  • the disease or condition is a hereditary genetic disease, or a disease or condition associated with one or more acquired genetic mutations (e.g., drug resistance).
  • the method further comprises obtaining the cell from the individual.
  • a method of treating or preventing a disease or condition in an individual comprising editing a target RNA associated with the disease or condition in a cell of the individual using any one of the methods of RNA editing described herein.
  • a method of treating or preventing a disease or condition in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a method of treating or preventing a disease or condition in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a targeting RNA sequence that hybridizes to the target RNA
  • small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence
  • a method of treating or preventing a disease or condition in an individual comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) oper
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the method further comprises culturing the cell having the edited RNA.
  • the method further comprises administering the cell having the edited RNA to the individual.
  • the disease or condition is a hereditary genetic disease, or a disease or condition associated with one or more acquired genetic mutations (e.g., drug resistance).
  • a method of treating or preventing a disease or condition in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a method of treating or preventing a disease or condition in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a method of treating or preventing a disease or condition in an individual comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the disease or condition is a hereditary genetic disease, or a disease or condition associated with one or more acquired genetic mutations (e.g., drug resistance).
  • Diseases and conditions suitable for treatment using the methods of the present application include diseases associated with a mutation, such as a G to A mutation, e.g., a G to A mutation that results in missense mutation, early stop codon, aberrant splicing, or alternative splicing in an RNA transcript.
  • a mutation such as a G to A mutation, e.g., a G to A mutation that results in missense mutation, early stop codon, aberrant splicing, or alternative splicing in an RNA transcript.
  • TP53 W53X e.g., 158G>A
  • IDUA W402X e.g., TGG>TAG mutation in exon 9
  • Mucopolysaccharidosis type I MPS I
  • COL3A1 W1278X e.g., 3833G>A mutation
  • BMPR2 W298X e.g., 893G>A
  • AHI1 W725X e.g., 2174G>A
  • FANCC W506X e.g., 1517G>A
  • MYBPC3 W1098X e.g., 3293G>A
  • primary familial hypertrophic cardiomyopathy e.g., 710G
  • a method of treating a cancer associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating a cancer associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating a cancer associated with a target RNA having a mutation comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is TP53 W53X (e.g., 158G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 4 (5′-GGGAGCAGCCUCUGGCAUUCUGGGAGCUUCAUCUGGACCUGGGUCUUCAGUGAAC CAUUGUUCAAUAUCGUCCGGGGACAGCAUCAAAUCAUCCAUUGCUUGGGACGGCA A-3′).
  • a method of treating or preventing a cancer with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing a cancer with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing a cancer with a target RNA having a mutation comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is TP53 W53X (e.g., 158G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 4.
  • a method of treating MPS I e.g., Hurler syndrome or Scheie syndrome
  • a target RNA having a mutation e.g., G>A mutation
  • the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a method of treating MPS I e.g., Hurler syndrome or Scheie syndrome
  • a target RNA having a mutation e.g., G>A mutation
  • the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • MPS I e.g., Hurler syndrome or Scheie syndrome
  • a method of treating MPS I e.g., Hurler syndrome or Scheie syndrome associated with a target RNA having a mutation (e.g., G>A mutation) in an individual, comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • MPS I e.g., Hurler syndrome or Scheie syndrome
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is IDUA W402X (e.g., TGG>TAG mutation in exon 9).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 5 (5′-GACGCCCACCGUGUGGUUGCUGUCCAGGACGGUCCCGGCCUGCGACACUUCGGCC CAGAGCUGCUCCUCAUCUGCGGGGCGGGGGGGGGCCGUCGCCGCGUGGGGUCGUU G-3′).
  • a method of treating or preventing MPS I with a target RNA having a mutation (e.g., G>A mutation) in an individual, comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • MPS I e.g., Hurler syndrome or Scheie syndrome
  • a method of treating or preventing MPS I with a target RNA having a mutation (e.g., G>A mutation) in an individual, comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • MPS I e.g., Hurler syndrome or Scheie syndrome
  • a method of treating or preventing MPS I with a target RNA having a mutation (e.g., G>A mutation) in an individual, comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • MPS I e.g., Hurler syndrome or Scheie syndrome
  • a target RNA having a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is IDUA W402X (e.g., TGG>TAG mutation in exon 9).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 5.
  • a method of treating a disease or condition Ehlers-Danlos syndrome associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating a disease or condition Ehlers-Danlos syndrome associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating a disease or condition Ehlers-Danlos syndrome associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is COL3A1 W1278X (e.g., 3833G>A mutation).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 6 (5′-CAUAUUACAGAAUACCUUGAUAGCAUCCAAUUUGCAUCCUUGGUUAGGGUCAAC CCAGUAUUCUCCACUCUUGAGUUCAGGAUGGCAGAAUUUCAGGUCUCUGCAGUU UCU-3′).
  • a method of treating or preventing Ehlers-Danlos syndrome with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Ehlers-Danlos syndrome with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Ehlers-Danlos syndrome with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is COL3A1 W1278X (e.g., 3833G>A mutation).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 6.
  • a method of treating primary pulmonary hypertension associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating primary pulmonary hypertension associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating primary pulmonary hypertension associated with a target RNA having a mutation comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is BMPR2 W298X (e.g., 893G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 7 (5′-GUGAAGAUAAGCCAGUCCUCUAGUAACAGAAUGAGCAAGACGGCAAGAGCUUAC CCAGUCACUUGUGUGGAGACUUAAAUACUUGCAUAAAGAUCCAUUGGGAUAGUA CUC-3′).
  • a method of treating or preventing primary pulmonary hypertension with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing primary pulmonary hypertension with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing primary pulmonary hypertension with a target RNA having a mutation comprising administering an effective amount of a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is BMPR2 W298X (e.g., 893G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 7.
  • a method of treating Joubert syndrome associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating Joubert syndrome associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual e vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating Joubert syndrome associated with a target RNA having a mutation comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is AHI1 W725X (e.g., 2174G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 8 (5′-GUGAACGUCAAACUGUCGGACCAAUAUGGCAGAAUCUUCUCUCAUCUCAACUUUC CAUAUCCGUAUCAUGGAAUCAUAGCAUCCUGUAACUACUCUCUUACAGCUG G-3′).
  • a method of treating or preventing Joubert syndrome with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Joubert syndrome with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Joubert syndrome with a target RNA having a mutation comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is AHI1 W725X (e.g., 2174G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 8.
  • a method of treating Fanconi anemia associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating Fanconi anemia associated with a target RNA having a mutation comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating Fanconi anemia associated with a target RNA having a mutation comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is FANCC W506X (e.g., 1517G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 9 (5′-GCCAAUGAUCUCGUGAGUUAUCUCAGCAGUGUGAGCCAUCAGGGUGAUGACAUC CCAGGCGAUCGUGUGGCCUCCAGGAGCCCAGAGCAGGAAGUUGAGGAGAAGGUG CCU-3′).
  • a method of treating or preventing Fanconi anemia with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Fanconi anemia with a target RNA having a mutation comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing Fanconi anemia with a target RNA having a mutation comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is FANCC W506X (e.g., 1517G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 9.
  • a method of treating primary familial hypertrophic cardiomyopathy associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating primary familial hypertrophic cardiomyopathy associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating primary familial hypertrophic cardiomyopathy associated with a target RNA having a mutation comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is MYBPC3 W1098X (e.g., 3293G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 10 (5′-CAAGACGGUGAACCACUCCAUGGUCUUCUUGUCGGCUUUCUGCACUGUGUACCCC CAGAGCUCCGUGUUGCCGACAUCCUGGGGUGGCUUCCACUCCAGAGCCACAUUAA G-3′).
  • a method of treating or preventing primary familial hypertrophic cardiomyopathy with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing primary familial hypertrophic cardiomyopathy with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing primary familial hypertrophic cardiomyopathy with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is MYBPC3 W1098X (e.g., 3293G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 10.
  • a method of treating X-linked severe combined immunodeficiency associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating X-linked severe combined immunodeficiency associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a dRNA or a construct comprising a nucleic acid encoding the dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating X-linked severe combined immunodeficiency associated with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising introducing a construct comprising a nucleic acid encoding a dRNA into an isolated cell of the individual ex vivo, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the isolated cell.
  • the method comprises introducing the ADAR or a construct comprising a nucleic acid encoding the ADAR to the isolated cell.
  • the target RNA is IL2RG W237X (e.g., 710G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 11 (5′-AGGAUUCUCUUUUGAAGUAUUGCUCCCCCAGUGGAUUGGGUGGCUCCAUUCACUC CAAUGCUGAGCACUUCCACAGAGUGGGUUAAAGCGGCUCCGAACACGAAACGUGU A-3′).
  • a method of treating or preventing X-linked severe combined immunodeficiency with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing X-linked severe combined immunodeficiency with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a dRNA or a construct comprising a nucleic acid encoding the dRNA to the individual, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • a mutation e.g., G>A mutation
  • a method of treating or preventing X-linked severe combined immunodeficiency with a target RNA having a mutation (e.g., G>A mutation) in an individual comprising administering an effective amount of a construct comprising a nucleic acid encoding a dRNA to the individual, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • a mutation e.g., G>A mutation
  • the ADAR is an endogenously expressed ADAR in the cells of the individual.
  • the method comprises administering the ADAR or a construct comprising a nucleic acid encoding the ADAR to the individual.
  • the target RNA is IL2RG W237X (e.g., 710G>A).
  • the dRNA comprises the nucleic acid sequence of SEQ ID NO: 11.
  • dosages, schedules, and routes of administration of the compositions may be determined according to the size and condition of the individual, and according to standard pharmaceutical practice.
  • routes of administration include intravenous, intra-arterial, intraperitoneal, intrapulmonary, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, or transdermal.
  • RNA editing methods of the present application not only can be used in animal cells, for example mammalian cells, but also may be used in modification of RNAs of plant or fungi, for example, in plants or fungi that have endogenously expressed ADARs.
  • the methods described herein can be used to generate genetically engineered plant and fungi with improved properties.
  • compositions comprising any one of the dRNAs, constructs, libraries, or host cells having edited RNA as described herein.
  • a pharmaceutical composition comprising any one of the dRNAs or constructs encoding the dRNA described herein, and a pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)).
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as olyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine
  • compositions to be used for in vivo administration must be sterile. This is readily accomplished by, e.g., filtration through sterile filtration membranes.
  • kits useful for any one of the methods of RNA editing or methods of treatment described herein comprising any one of the dRNAs, constructs, compositions, libraries, or edited host cells as described herein.
  • a kit for editing a target RNA in a host cell comprising a dRNA or a construct comprising a nucleic acid encoding the dRNA, wherein the dRNA comprises a targeting RNA sequence that hybridizes to a target RNA associated with the disease or condition, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA and wherein the dRNA is and wherein the dRNA is a circular RNA or capable of forming a circular RNA.
  • a kit for editing a target RNA in a host cell comprising a dRNA or a construct comprising a nucleic acid encoding the dRNA, wherein the dRNA comprises a (1) targeting RNA sequence that hybridizes to the target RNA and (2) a small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence, and wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA.
  • snoRNA small nucleolar RNA
  • kits for editing a target RNA in a host cell comprising or a construct comprising a nucleic acid encoding a dRNA, wherein the dRNA comprises a targeting RNA sequence that hybridizes to the target RNA, wherein the dRNA is capable of recruiting an ADAR to deaminate a target adenosine residue in the target RNA, and wherein the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • Poly II promoter polymerase II promoter
  • the kit further comprises an ADAR or a construct comprising a nucleic acid encoding an ADAR. In some embodiments, the kit further comprises an inhibitor of ADAR3 or a construct thereof. In some embodiments, the kit further comprises a stimulator of interferon or a construct thereof. In some embodiments, the kit further comprises an instruction for carrying out any one of the RNA editing methods or methods of treatment described herein.
  • kits of the present application are in suitable packaging.
  • suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Kits may optionally provide additional components such as transfection or transduction reagents, cell culturing medium, buffers, and interpretative information.
  • the present application thus also provides articles of manufacture.
  • the article of manufacture can comprise a container and a label or package insert on or associated with the container.
  • Suitable containers include vials (such as sealed vials), bottles, jars, flexible packaging, and the like.
  • the container holds a pharmaceutical composition, and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the container holding the pharmaceutical composition may be a multi-use vial, which allows for repeat administrations (e.g. from 2-6 administrations) of the reconstituted formulation.
  • Package insert refers to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such products.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline. Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • BWFI bacteriostatic water for injection
  • kits or article of manufacture may include multiple unit doses of the pharmaceutical compositions and instructions for use, packaged in quantities sufficient for storage and use in pharmacies, for example, hospital pharmacies and compounding pharmacies.
  • a method for editing a target RNA in a host cell comprising introducing a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid encoding the dRNA into the host cell, wherein:
  • dRNA deaminase-recruiting RNA
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the dRNA is a circular RNA or capable of forming a circular RNA.
  • the dRNA further comprises a 3′ ligation sequence and a 5′ ligation sequence.
  • the 3′ ligation sequence and the 5′ ligation sequence are at least partially complementary to each other.
  • the 3′ ligation sequence and the 5′ ligation sequence are about 20 to about 75 nucleotides in length.
  • the method of any one of embodiments 1-4, wherein the dRNA is circularized by RNA ligase RtcB. 6.
  • the method of embodiment 4, wherein the RNA ligase RtcB is expressed endogenously in the host cell. 7.
  • the dRNA is a linear RNA capable of forming a circular RNA.
  • the method comprises introducing a construct comprising a nucleic acid encoding the dRNA into the host cell.
  • the construct further comprises a 3′ twister ribozyme sequence linked to the 3′ end of the nucleic acid encoding the dRNA and a 5′ twister ribozyme sequence linked to the 5′ end of the nucleic acid encoding the dRNA.
  • the 3′ twister sequence is twister P3 U2A and the 5′ twister sequence is twister P1.
  • a method for editing a target RNA in a host cell comprising introducing a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid encoding the dRNA into the host cell, wherein the dRNA comprises:
  • RNA sequence that is at least partially complementary to the target RNA
  • small nucleolar RNA (snoRNA) sequence linked to the 3′ and/or 5′ ends of the targeting RNA sequence
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).
  • ADAR adenosine deaminase acting on RNA
  • the dRNA comprises a snoRNA sequence linked to the 5′ end of the targeting RNA sequence (“5′ snoRNA sequence”).
  • the dRNA comprises a snoRNA sequence linked to the 3′ end of the targeting RNA sequence (3′ snoRNA sequence”).
  • the snoRNA sequence is at least about 70 nucleotides in length.
  • the 3′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 1. 18.
  • the 5′ snoRNA sequence comprises the nucleic acid sequence of SEQ ID NO: 2. 19.
  • the method of any one of embodiments 13-18, wherein the snoRNA sequence is a C/D Box snoRNA sequence.
  • the snoRNA sequence is an H/ACA Box snoRNA sequence.
  • the method of any one of embodiments 13-18, wherein the snoRNA sequence is a composite C/D Box and H/ACA Box snoRNA sequence.
  • the snoRNA sequence is an orphan snoRNA sequence. 23.
  • any one of embodiments 13-22 wherein the method comprises introducing a construct comprising a nucleic acid encoding the dRNA into the host cell.
  • 24. The method of embodiment any one of embodiments 9-12 and 23, wherein the construct further comprises a promoter operably linked to the nucleic acid encoding the dRNA.
  • 25. The method of embodiment 24, wherein the promoter is a polymerase II promoter (“Pol II promoter”).
  • Poly II promoter polymerase II promoter
  • a method for editing a target RNA in a host cell comprising introducing a construct comprising a nucleic acid encoding a deaminase-recruiting RNA (dRNA) into the host cell, wherein:
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • Polymerase II promoter operably linked to the nucleic acid encoding the dRNA.
  • the targeting RNA sequence is about 100 to about 150 nucleotides in length.
  • 35. The method of any one of embodiments 1-34, wherein the targeting RNA sequence comprises a cytidine, adenosine or uridine directly opposite the target adenosine in the target RNA.
  • 36. The method of embodiment 35, wherein the targeting RNA sequence comprises a cytidine mismatch directly opposite the target adenosine in the target RNA.
  • the cytidine mismatch is located at least 20 nucleotides away from the 3′ end of the targeting RNA sequence, and at least 5 nucleotides away from the 5′ end of the targeting RNA sequence. 38.
  • the targeting RNA sequence further comprises one or more guanosines each opposite a non-target adenosine in the target RNA. 39. The method of any one of embodiments 1-38, wherein the targeting RNA sequence comprises two or more consecutive mismatch nucleotides opposite a non-target adenosine in the target RNA. 40.
  • the target adenosine is in a three-base motif selected from the group consisting of UAG, UAC, UAA, UAU, CAG, CAC, CAA, CAU, AAG, AAC, AAA, AAU, GAG, GAC, GAA and GAU in the target RNA.
  • the three-base motif is UAG
  • the targeting RNA comprises an A directly opposite the uridine in the three-base motif, a cytidine directly opposite the target adenosine, and a cytidine, guanosine or uridine directly opposite the guanosine in the three-base motif.
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA. 44. The method of embodiment 43, wherein the target RNA is a pre-messenger RNA. 45. The method of any one of embodiments 1-44, further comprising introducing an inhibitor of ADAR3 and/or to the host cell. 46. The method of any one of embodiments 1-45, further comprising introducing a stimulator of interferon to the host cell. 47.
  • the method of any one of embodiments 1-46 comprising introducing a plurality of dRNAs or constructs each targeting a different target RNA.
  • 48. The method of any one of embodiments 1-47, wherein the efficiency of editing the target RNA is at least 40%.
  • 49. The method of any one of embodiments 1-48, wherein the construct or the dRNA does not induce immune response.
  • 50. The method of any one of embodiments 149, further comprising introducing an ADAR (e.g., exogenous ADAR) to the host cell.
  • an ADAR e.g., exogenous ADAR
  • a method for treating or preventing a disease or condition in an individual comprising editing a target RNA associated with the disease or condition in a cell of the individual according to the method of any one of the embodiments 1-57.
  • the method of embodiment 58, wherein the disease or condition is a hereditary genetic disease or a disease or condition associated with one or more acquired genetic mutations.
  • 60. The method of embodiment 58 or 59, wherein the target RNA has a G to A mutation.
  • the method of any one of embodiments 58-60, wherein disease or condition is a monogenetic disease or condition.
  • the dRNA comprises a targeting RNA sequence that is at least partially complementary to the target RNA
  • the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR), and
  • the construct comprises a polymerase II promoter (“Pol II promoter”) operably linked to the nucleic acid encoding the dRNA.
  • Polymerase II promoter operably linked to the nucleic acid encoding the dRNA.
  • the target RNA is an RNA selected from the group consisting of a pre-messenger RNA, a messenger RNA, a ribosomal RNA, a transfer RNA, a long non-coding RNA and a small RNA.
  • a host cell comprising the construct or dRNA of any one of embodiments 64-91.
  • a kit for editing a target RNA in a host cell comprising the construct or dRNA of any one of embodiments 64-91.
  • the dual fluorescence reporter was cloned by PCR amplifying mCherry and EGFP (the EGFP first codon ATG was deleted) coding DNA, the 3 ⁇ GS linker and targeting DNA sequence were added via primers during PCR. Then the PCR products were cleaved and linked by Type IIs restriction enzyme BsmB1 (Thermo) and T4 DNA ligase (NEB), which then were inserted into pLenti backbone (pLenti-CMV-MCS-SV-Bsd, Stanley Cohen Lab, Stanford University).
  • BsmB1 Thermo
  • NEB T4 DNA ligase
  • the dLbuCas13 DNA was PCR amplified from the Lbu plasmids (Addgene #83485).
  • the ADAR1DD and ADAR2DD were amplified from Adar1(p150) cDNA and Adar2 cDNA, both of which were gifts from Han's lab at Xiamen University.
  • the ADAR1DD or ADAR2DD were fused to dLbuCas13 DNA by overlap-PCR, and the fused PCR products were inserted into pLenti backbone.
  • dRNA sequences were directly synthesized (for short dRNAs) and annealed or PCR amplified by synthesizing overlapping ssDNA, and the products were cloned into the corresponding vectors under U6 expression by Golden-gate cloning.
  • Adar1(p110) and Adar1(p150) were PCR amplified from Adar1(p150) cDNA, and the full length Adar2 were PCR amplified from Adar2 cDNA, which were then cloned into pLenti backbone, respectively.
  • mCherry and EGFP (the start codon ATG of EGFP was deleted) coding sequences were PCR amplified, digested using BsmBI (Thermo Fisher Scientific, ER0452), followed by T4 DNA ligase (NEB, M0202L)-mediated ligation with GGGGS linkers. The ligation product was subsequently inserted into the pLenti-CMV-MCS-PURO backbone.
  • the ADAR1 DD gene was amplified from the ADAR1 p150 construct (a gift from Jiahuai Han's lab, Xiamen University).
  • the dLbuCas13 gene was amplified by PCR from the Lbu_C2c2_R472A_H477A_R1048A_H1053A plasmid (Addgene #83485).
  • the ADAR1 DD (hyperactive E1008Q variant) was generated by overlap-PCR and then fused to dLbuCas13.
  • the ligation products were inserted into the pLenti-CMV-MCS-BSD backbone.
  • arRNA-expressing construct the sequences of arRNAs were synthesized and golden-gate cloned into the pLenti-sgRNA-lib 2.0 (Addgene #89638) backbone, and the transcription of arRNA was driven by hU6 promoter.
  • the full length ADAR1 p110 and ADAR1 p150 were PCR amplified from the ADAR1 p150 construct, and the full length ADAR2 were PCR amplified from the ADAR2 construct (a gift from Jiahuai Han's lab, Xiamen University). The amplified products were then cloned into the pLenti-CMV-MCS-BSD backbone.
  • Mammalian cell lines were cultured Dulbecco's Modified Eagle Medium (10-013-CV, Corning, Tewksbury, Mass., USA), adding 10% fetal bovine serum (Lanzhou Bailing Biotechnology Co., Ltd., Lanzhou, China), supplemented with 1% penicillin-streptomycin under 5% CO 2 at 37° C.
  • the Adar1-KO cell line was purchased from EdiGene China, and the genotyping results were also provided by EdiGene China.
  • the HeLa and B16 cell lines were from Z. Jiang's laboratory (Peking University). And the HEK293T cell line was from C. Zhang's laboratory (Peking University). RD cell line was from J Wang's laboratory (Institute of Pathogen Biology, Peking Union Medical College & Chinese Academy of Medical Sciences). SF268 cell lines were from Cell Center, Institute of Basic Medical Sciences. Chinese Academy of Medical Sciences. A549 and SW13 cell lines were from EdiGene Inc. HepG2, HT29, NIH3T3, and MEF cell lines were maintained in our laboratory at Peking University.
  • the human primary pulmonary fibroblasts (#3300) and human primary bronchial epithelial cells (#3210) were purchased from ScienCell Research Laboratories, Inc. and were cultured in Fibroblast Medium (ScienCell, #2301) and Bronchial Epithelial Cell Medium (ScienCell, #3211), respectively. Both media were supplemented with 15% fetal bovine serum (BI) and 1% penicillin-streptomycin.
  • the primary GM06214 and GM01323 cells were ordered from Coriell Institute for Medical Research and cultured in Dulbecco's Modified Eagle Medium (Corning, 10-013-CV) with 15% fetal bovine serum (BI) and 1% penicillin-streptomycin. All cells were cultured under 5% CO 2 at 37° C.
  • 293T-WT cells or 293T-Adar1-KO cells were seeded in 6 wells plates (6 ⁇ 10 5 cells/well), 24 hours later, 1.5 ⁇ g reporter plasmids and 1.5 ⁇ g dRNA plasmids were co-transfected using the X-tremeGENE HP DNA transfection reagent (06366546001; Roche, Mannheim, German), according to the supplier's protocols. 48 to 72 hours later, collected cells and performed FACS analysis.
  • Adar1(p110), Adar1(p150) or Adar2 rescue and overexpression experiments 293T-WT cells or 293T-Adar1-KO cells were seeded in 12 wells plates (2.5 ⁇ 10 5 cells/well), 24 hours later, 0.5 ⁇ g reporter plasmids, 0.5 ⁇ g dRNA plasmids and 0.5 ⁇ g Adar1/2 plasmids (pLenti backbone as control) were co-transfected using the X-tremeGENE HP DNA transfection reagent (06366546001, Roche, Mannheim. German). 48 to 72 hours later, collected cells and performed FACS analysis.
  • RNA isolation For endogenous mRNA experiments, 293T-WT cells were seeded in 6 wells plates (6 ⁇ 10 5 cells/well), When approximately 70% confluent, 3 ⁇ g dRNA plasmids were transfected using the X-tremeGENE HP DNA transfection reagent (06366546001, Roche. Mannheim, German). 72 hours later, collected cells and sorted GFP-positive or BFP-positive cells (according to the corresponding fluorescence maker) via FACS for the following RNA isolation.
  • X-tremeGENE HP DNA transfection reagent 6366546001, Roche. Mannheim, German
  • PBMCs Peripheral blood mononuclear cells
  • T cells were isolated by Ficoll centrifugation (Dakewei, AS1114546), and T cells were isolated by magnetic negative selection using an EasySep Human T Cell Isolation Kit (STEMCELL, 17951) from PBMCs.
  • PBMCs Peripheral blood mononuclear cells
  • T cells were cultured in X-vivo15 medium, 10% FBS and IL2 (1000 U/ml) and stimulated with CD3/CD28 DynaBeads (ThermoFisher, 11131D) for 2 days.
  • Leukapheresis products from healthy donors were acquired from AllCells LLC China. All healthy donors provided informed consent.
  • the expression plasmid was co-transfected into HEK293T-WT cells, together with two viral packaging plasmids, pR8.74 and pVSVG (Addgene) via the X-tremeGENE HP DNA transfection reagent. 72 hours later, the supernatant virus was collected and stored at ⁇ 80° C.
  • the HEK293T-WT cells were infected with lenti-virus, 72 hours later, mCherry-positive cells were sorted via FACS and cultured to select a single clone cell lines stably expressing dual fluorescence reporter system with much low EGFP background by limiting dilution method.
  • the reporter constructs (pLenti-CMV-MCS-PURO backbone) were co-transfected into HEK293T cells, together with two viral packaging plasmids, pR8.74 and pVSVG. 72 hours later, the supernatant virus was collected and stored at ⁇ 80° C.
  • the HEK293T cells were infected with lentivirus, then mCherry-positive cells were sorted via FACS and cultured to select a single clone cell lines stably expressing dual fluorescence reporter system without detectable EGFP background.
  • the HEK293T ADAR1 ⁇ / ⁇ and TPS3 ⁇ / ⁇ cell lines were generated according to a previously reported method 60 .
  • ADAR1-targeting sgRNA and PCR amplified donor DNA containing CMV-driven puromycin resistant gene were co-transfected into HEK293T cells. Then cells were treated with puromycin 7 days after transfection. Single clones were isolated from puromycin resistant cells followed by verification through sequencing and Western blot.
  • HEK293T cells or HEK293T ADAR1 ⁇ / ⁇ cells were seeded in 6-well plates (6 ⁇ 10 5 cells/well). 24 hours later, cells were co-transfected with 1.5 ⁇ g reporter plasmids and 1.5 ⁇ g arRNA plasmids.
  • ADAR1 p110 , ADAR1 p150 or ADAR2 protein expression the editing efficiency was assayed by EGFP positive ratio and deep sequencing.
  • HEK293T ADAR1 ⁇ / ⁇ cells were seeded in 12-well plates (2.5 ⁇ 10 5 cells/well). 24 hours later, cells were co-transfected with 0.5 ⁇ g of reporter plasmids, 0.5 ⁇ g arRNA plasmids and 0.5 ⁇ g ADAR1/2 plasmids (pLenti backbone as control). The editing efficiency was assayed by EGFP positive ratio and deep sequencing.
  • HEK293T cells were seeded in 6-well plates (6 ⁇ 10 5 cells/well). Twenty-four hours later, cells were transfected with 3 ⁇ g of arRNA plasmids. The editing efficiency was assayed by deep sequencing.
  • RNA editing efficiency in multiple cell lines 8-9 ⁇ 104 (RD, SF268, HeLa) or 1.5 ⁇ 10 5 (HEK293T) cells were seeded in 12-well plates.
  • RD RD
  • SF268, HeLa 1.5 ⁇ 10 5
  • 2-2.5 ⁇ 10 5 cells were seeded in 6-well plate. Twenty-four hours later, reporters and arRNAs plasmid were co-transfected into these cells. The editing efficiency was assayed by EGFP positive ratio.
  • EGFP positive ratio At 48 to 72 hrs post transfection, cells were sorted and collected by Fluorescence-activated cell sorting (FACS) analysis.
  • FACS Fluorescence-activated cell sorting
  • the mCherry signal was served as a fluorescent selection marker for the reporter/arRNA-expressing cells, and the percentages of EGFP + /mCherry + cells were calculated as the readout for editing efficiency.
  • RNA isolation TIANGEN, DP420. Then, the total RNAs were reverse-transcribed into cDNA via RT-PCR (TIANGEN, KR103-04), and the targeted locus was PCR amplified with the corresponding primers listed in the following table.
  • PCR products were purified for Sanger sequencing or NGS (Illumina HiSeq X Ten).
  • HEK293T positive control
  • HEK293T ADAR1 ⁇ / ⁇ negative control
  • NIH3T3 seven human cell lines
  • RD, HeLa, SF268, A549, HepG2, HT-29, SW13 human cell lines
  • HEK293T 1.5 ⁇ 10 5
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • CG2 reporter and 71 nt dRNA (35-C-35) plasmid were co-transfected into different type of cells with X-tremeGENE HP DNA transfection reagent (Roche).
  • FACS X-tremeGENE HP DNA transfection reagent
  • RNA Polymerase II (Pol II)
  • a plasmid expressing arRNA driven by a Pol II promoter (CMV) was constructed.
  • CMV RNA Polymerase II promoter
  • reporter 1 reporter system based on EGFP expression
  • Untreated cells were used as a mock control (Mock).
  • Cells transfected with a non-targeting RNA were also used as a control (Ctrl RNAs). It was found that CMV-arRNA outperforms U6-arRNA in RNA editing ( FIG. 1 ).
  • arRNA was engineered to have snoRNA ends.
  • the 151-nt arRNA targeting fluorescence Reporter-1 was flanked with snoRNA ends ( FIG. 2A ):
  • Dual fluorescence reporter-1 comprises sequence of mCherry (SEQ ID NO: 21), sequence comprising 3 ⁇ GS linker and the targeted A (SEQ ID NO: 22), and sequence of eGFP (SEQ ID NO: 23).
  • the human U6-drived sno-arRNA151, arRNA151, sno-Ctrl RNA151 or Ctrl RNA151 was transfected into HEK293T cells along with Reporter-expressing plasmids. Forty-eight hours post transfection, the EGFP positive rate was quantified via FACS analysis. The FACS results showed sno-arRNA151 flanked by snoRNA ends could mediated targeted RNA editing on Reporter mRNA with almost 38% EGFP positive rate, lower than that of the linear arRNAs ( FIGS. 2B-2C ).
  • the EGPF positive rate was measured at different time points.
  • the sno-arRNA 151 , arRNA 151 , sno-Ctrl RNA 151 or Ctrl RNA 151 under human U6 promoter were transfected into HEK293T-Reporter cells.
  • the EGFP positive rate was measured at 3 times points: 3 days, 6 days and 12 days post transfection.
  • the results showed that sno-arRNA exhibited higher editing efficiency than arRNA during the extended time period, indicating that snoRNA ends could protect arRNA from degradation and enhance the abundance of sno-arRNA ( FIG. 3A ).
  • CMV_arRNA CMV-promoter expressed arRNA
  • U6_promoter expressed arRNA U6_promoter expressed arRNA
  • CMV_sno-arRNA CMV-promoter expressed sno-arRNA
  • U6_sno-arRNA U6-promoter expressed sno-arRNA
  • HEK293T cells stably expressing the Reporter-1 containing an in-frame stop codon between mCherry and EGFP ( FIG. 4B ) were transfected with plasmids expressing circular arRNA 71 and circular arRNA 111 both targeting the Reporter-1.
  • the EGFP fluorescence indicates the efficiency of target editing on RNA.
  • circular arRNAs were flanked with 25-nt or 50-nt linker connecting to both ends ligation sequence ( FIG. 4A ).
  • linear (non-circular) arRNA 71 and arRNA 111 were also transfected at the same time. It turned out that circular arRNAs strongly improved both the ratios of EGFP + cells and EGFP intensity ( FIG. 4C ) compared with linear arRNAs, while circular arRNA with 25-nt or 50-nt linker weakened the improvement of efficiency ( FIG. 4C ).
  • Dual fluorescence reporter-3 comprises sequence of mCherry (SEQ ID NO:21), sequence comprising 1 ⁇ GS linker (shown as italic and bold characters) and the targeted A (SEQ ID NO:24), and sequence of eGFP (SEQ ID NO:23).
  • the circular arRNAs were used in HeLa and A549 cells in which LEAPER efficiencies are relatively low among multiple cell lines we have tested because of low expression level of ADAR1 or high expression of ADAR3. It turned out that circular arRNAs significantly boosted the editing efficiency in both cell lines based on EGFP reporter assays ( FIG. 4E ).
  • RG6 splicing reporter was used to test if LEAPER-circular arRNAs could change splicing acceptor site.
  • Three versions of circular arRNAs were designed to target RG6 splicing acceptor site, including Tornado-arRNA 71 (71-nt), Tornado-arRNA 71 (111-nt), and Tornado-arRNA 71+BP (111-nt targeting both acceptor site and a branch point).
  • the RG6 reporter expressed more dsRNA protein over EGFP protein if the splicing if the splicing pattern was changed by LEAPER-Tornado ( FIG. 6A ).
  • LEAPER-circular arRNAs can efficiently target the cellular splicing machinery ( FIG. 6B ).
US17/626,440 2019-07-12 2020-07-10 Targeted rna editing by leveraging endogenous adar using engineered rnas Pending US20220243194A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/095802 2019-07-12
CN2019095802 2019-07-12
PCT/CN2020/101246 WO2021008447A1 (en) 2019-07-12 2020-07-10 Targeted rna editing by leveraging endogenous adar using engineered rnas

Publications (1)

Publication Number Publication Date
US20220243194A1 true US20220243194A1 (en) 2022-08-04

Family

ID=74210191

Family Applications (3)

Application Number Title Priority Date Filing Date
US17/626,440 Pending US20220243194A1 (en) 2019-07-12 2020-07-10 Targeted rna editing by leveraging endogenous adar using engineered rnas
US17/573,525 Active 2040-08-01 US11661596B2 (en) 2019-07-12 2022-01-11 Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs
US18/303,505 Pending US20230365962A1 (en) 2019-07-12 2023-04-19 Targeted rna editing by leveraging endogenous adar using engineered rnas

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/573,525 Active 2040-08-01 US11661596B2 (en) 2019-07-12 2022-01-11 Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs
US18/303,505 Pending US20230365962A1 (en) 2019-07-12 2023-04-19 Targeted rna editing by leveraging endogenous adar using engineered rnas

Country Status (16)

Country Link
US (3) US20220243194A1 (zh)
EP (1) EP3997229A1 (zh)
JP (1) JP2022536546A (zh)
KR (1) KR20220038706A (zh)
CN (2) CN117778385A (zh)
AU (1) AU2020313143B2 (zh)
BR (1) BR112022000291A2 (zh)
CA (1) CA3146771A1 (zh)
CL (1) CL2022000080A1 (zh)
CO (1) CO2022001359A2 (zh)
CR (1) CR20220063A (zh)
EC (1) ECSP22010372A (zh)
IL (1) IL289700A (zh)
MX (1) MX2022000497A (zh)
PE (1) PE20220300A1 (zh)
WO (1) WO2021008447A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702658B2 (en) 2019-04-15 2023-07-18 Edigene Therapeutics (Beijing) Inc. Methods and compositions for editing RNAs

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220300A1 (es) 2019-07-12 2022-03-09 Univ Beijing Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
CA3159944A1 (en) 2019-12-02 2021-06-10 David HUSS Therapeutic editing
WO2021209010A1 (zh) * 2020-04-15 2021-10-21 博雅辑因（北京）生物科技有限公司 一种治疗赫勒氏综合征的方法和药物
WO2021242889A1 (en) * 2020-05-26 2021-12-02 Shape Therapeutics Inc. Engineered circular polynucleotides
AU2022285744A1 (en) * 2021-06-02 2023-12-14 Beam Therapeutics Inc. Circular guide rnas for crispr/cas editing systems
TW202321451A (zh) * 2021-08-18 2023-06-01 北京大學 工程化的 adar 招募 rnas 及其使用方法
WO2023143538A1 (zh) * 2022-01-28 2023-08-03 北京辑因医疗科技有限公司 基于leaper技术治疗mpsi的方法和组合物
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2023237063A1 (en) * 2022-06-08 2023-12-14 Huidagene Therapeutics Co., Ltd. Novel guide nucleic acids for rna base editing systems and uses thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
EP2630241B1 (en) 2010-10-22 2018-10-17 CuRNA, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US9650627B1 (en) * 2012-07-19 2017-05-16 University Of Puerto Rico Site-directed RNA editing
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
WO2016094845A2 (en) 2014-12-12 2016-06-16 Woolf Tod M Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
DK3234134T3 (da) 2014-12-17 2020-07-27 Proqr Therapeutics Ii Bv Målrettet rna-redigering
EP3323890A4 (en) 2015-07-14 2019-01-30 Fukuoka University METHOD FOR INDUCING SITE SPECIFIC RNA MUTATIONS, TARGET EDITION GUIDING RNA-GUIDE USED IN THE METHOD, AND TARGET EDITING GUID-RNA TARGET RNA COMPLEX
DE102015012522B3 (de) 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Verfahren und Substanzen zur gerichteten RNA-Editierung
JP7043082B2 (ja) 2016-04-25 2022-03-29 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 眼疾患を処置するオリゴヌクレオチド
JP7074345B2 (ja) 2016-06-22 2022-05-24 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 一本鎖ｒｎａ編集オリゴヌクレオチド
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
WO2018041873A1 (en) 2016-09-01 2018-03-08 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
GB201616202D0 (en) 2016-09-23 2016-11-09 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of eye deisease
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
WO2018161032A1 (en) * 2017-03-03 2018-09-07 The Regents Of The University Of California RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
CA3062595A1 (en) 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
US20200248169A1 (en) 2017-06-26 2020-08-06 The Broad Institute, Inc. Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing
CN111511388A (zh) 2017-09-21 2020-08-07 博德研究所 用于靶向核酸编辑的系统、方法和组合物
US11788088B2 (en) * 2017-09-26 2023-10-17 The Board Of Trustees Of The University Of Illinois CRISPR/Cas system and method for genome editing and modulating transcription
CN111727247A (zh) 2017-10-04 2020-09-29 博德研究所 用于靶向核酸编辑的系统、方法和组合物
JP7402163B2 (ja) 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー ２ａ型アッシャー症候群の処置のための材料および方法
WO2019158475A1 (en) 2018-02-14 2019-08-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for rna editing
WO2019183641A1 (en) 2018-03-23 2019-09-26 Massachusetts Eye And Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome
WO2020001793A1 (en) 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
GB2590880A (en) * 2018-09-06 2021-07-07 Univ California RNA and DNA base editing via engineered ADAR recruitment
JP7252328B2 (ja) 2018-10-12 2023-04-04 北京大学 Ｒｎａを編集する方法および組成物
KR20210106527A (ko) 2018-12-20 2021-08-30 페킹 유니버시티 바코드화 가이드 rna 구축물을 사용한 고효율의 유전자 스크리닝을 위한 조성물 및 방법
CN114040970A (zh) 2019-02-13 2022-02-11 比姆医疗股份有限公司 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法，包括遗传性疾病的治疗
CN109943586B (zh) 2019-03-15 2021-02-26 上海交通大学 一种植物circRNA过表达载体及其构建方法
WO2020192712A1 (en) 2019-03-26 2020-10-01 Peking University Method for identifying functional elements
BR112021020608A8 (pt) 2019-04-15 2023-03-21 Univ Beijing Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit
CA3138029A1 (en) 2019-04-30 2020-11-05 Edigene Inc. Method for predicting effectiveness of treatment of hemoglobinopathy
PE20220300A1 (es) 2019-07-12 2022-03-09 Univ Beijing Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
CA3150230A1 (en) 2019-09-04 2021-03-11 Pengfei YUAN METHOD FOR EVALUATING GENE EDITING THERAPY BASED ON OFF-TARGET EVALUATION
TW202136503A (zh) 2019-12-16 2021-10-01 大陸商廣州輯因醫療科技有限公司 擴增造血幹細胞的小分子化合物及其組合
US20230060518A1 (en) 2019-12-30 2023-03-02 Edigene Therapeutics (Beijing) Inc. Leaper technology based method for treating mps ih and composition
KR20220118512A (ko) 2019-12-30 2022-08-25 에디진 테라퓨틱스 (베이징) 인크. 어셔 증후군의 치료 방법 및 그것의 조성물
EP4085931A4 (en) 2019-12-31 2024-01-17 Edigene Therapeutics Beijing Inc NEW PROCESS FOR TARGETED RNA EDITING
WO2022150974A1 (en) 2021-01-12 2022-07-21 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702658B2 (en) 2019-04-15 2023-07-18 Edigene Therapeutics (Beijing) Inc. Methods and compositions for editing RNAs

Also Published As

Publication number Publication date
EP3997229A1 (en) 2022-05-18
CN117778385A (zh) 2024-03-29
AU2020313143B2 (en) 2024-04-04
US11661596B2 (en) 2023-05-30
MX2022000497A (es) 2022-02-03
CA3146771A1 (en) 2021-01-21
ECSP22010372A (es) 2022-03-31
CR20220063A (es) 2022-07-22
CN114269919B (zh) 2023-08-18
CO2022001359A2 (es) 2022-05-10
CN114269919A (zh) 2022-04-01
US20230365962A1 (en) 2023-11-16
JP2022536546A (ja) 2022-08-17
AU2020313143A1 (en) 2022-02-10
US20220135963A1 (en) 2022-05-05
BR112022000291A2 (pt) 2022-03-15
KR20220038706A (ko) 2022-03-29
PE20220300A1 (es) 2022-03-09
CL2022000080A1 (es) 2022-11-18
IL289700A (en) 2022-03-01
WO2021008447A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US11661596B2 (en) Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs
US11702658B2 (en) Methods and compositions for editing RNAs
AU2019357450B2 (en) Methods and compositions for editing RNAs
WO2022150974A1 (en) Targeted rna editing by leveraging endogenous adar using engineered rnas
US20200263206A1 (en) Targeted integration systems and methods for the treatment of hemoglobinopathies
WO2023020574A1 (en) Engineered adar-recruiting rnas and methods of use thereof
WO2023185231A1 (en) Engineered adar-recruiting rnas and methods of use for usher syndrome
WO2023143539A1 (en) Engineered adar-recruiting rnas and methods of use thereof
WO2023196772A1 (en) Novel rna base editing compositions, systems, methods and uses thereof
CA3224369A1 (en) Compositions and methods for myosin heavy chain base editing

Legal Events

Date Code Title Description
AS Assignment

Owner name: PEKING UNIVERSITY, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEI, WENSHENG;YI, ZONGYI;QU, LIANG;AND OTHERS;REEL/FRAME:059714/0371

Effective date: 20220214

Owner name: PEKING UNIVERSITY, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEI, WENSHENG;YI, ZONGYI;QU, LIANG;AND OTHERS;REEL/FRAME:059836/0156

Effective date: 20220214

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION